Small Molecule Activation of Yap for Inner-Ear Regeneration and Beyond

Nathaniel Kastan

Follow this and additional works at: https://digitalcommons.rockefeller.edu/student_theses_and_dissertations

Part of the Life Sciences Commons
SMALL-MOLECULE ACTIVATION OF YAP FOR INNER-EAR REGENERATION – AND BEYOND

A Thesis Presented to the Faculty of the Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy

by
Nathaniel Kastan
June 2020
Hippo signaling is an evolutionarily conserved pathway that restricts organ growth during development and suppresses regeneration in mature organs. Using a high-throughput phenotypic screen, we have identified a potent, non-toxic, and reversible inhibitor of Hippo signaling. An ATP-competitive inhibitor of Lats kinases, the compound causes Yap-dependent proliferation of murine supporting cells in the inner ear, murine cardiomyocytes, and human Müller glia in retinal organoids. The compound promotes the initial stages of the proliferative regeneration of hair cells, a process thought to be permanently suppressed in the adult mammalian inner ear. In conjunction with the Tri-Institutional Therapeutics Discovery Institute, we have thoroughly characterized the compound and generated a suite of over 60 derivatives with improved characteristics such as potency, pharmacokinetics, and specificity. Together, these compounds offer powerful tools for molecular investigations of development, stem cell biology, and regeneration; it is even plausible that drugs related to this novel thiazolimine class will prove useful in therapeutic contexts.
Dedicated to my parents, whose only expectations were to do my best and to do good
Acknowledgements

This work has been made possible by a confluence of extraordinary people, both professionals and students alike on the Tri-Institutional campuses, as well as many people in my personal life who have helped me get to where I am today.

The Tri-Institutional MD-PhD program accepted me into their community and has since fostered my education and enabled my development as a scientist and a future physician. A special thank you to the pillars of that community, Dr. Olaf Andersen, Catharine Boothroyd, and Ruth Gotian.

This project was enabled by the hard work of scientists from two Tri-Institutional groups in particular. Much of this project wouldn’t have been possible without the expertise and effort of members of the High Throughput Resource Center: Jeanne Chiaravalli, Carolina Adura Alcaino, and Fraser Glickman. The Tri-Institutional Therapeutics Discovery Institute also played a key role. That group offered their wide array of expertise and were instrumental in assay design and optimization, as well driving the entirety of the medicinal chemistry effort. They expanded our knowledge and research quality well beyond what would have otherwise been possible. Thank you to Drs. Peter Meinke, Leigh Baxt, Rui Liang, Dave Huggins, John Ginn, Nigel Liverton, Stacia Kargman, and Rachel Kelly.

Early on in our project it became clear that TRULI may have broad utility. We have been fortunate to have fantastic collaborators who have helped us establish this part of our story. At Children’s Hospital of L.A., Dr. Aaron Nagiel was gracious enough to test our compound, offer unique insights, and expand our project into the retina. At
the Weissman Institute, Dr. Eldad Tzahor, and two members of his laboratory, Dr. Alla Aharanov and Avraham Shakked, spent months going back and forth with us regarding assay design, results, interpretation, and redesign. I have been very fortunate to find such fantastic collaborators, and the project wouldn’t be what it is without their expertise and efforts.

Thank you to my faculty committee members, Drs. Elaine Fuchs, Ali Brivanlou, and Kat Hadjantonakis. All of the faculty meetings have yielded helpful insights and guidance, and their support has been instrumental. Thank you also to Dr. Duojia Pan for taking the time to join as an external advisor.

Some of the many reasons I joined the Hudspeth lab were that I heard the environment was supportive, broad in their expertise, and a great group of people to work with. These aspects have all proven true and more so. Our lab wouldn’t run without Masha Vologodskiaia, who helped train me in a variety of techniques and is truly the mother of the lab, for her caring and thoughtful demeanor. I must also thank Beth Dougherty and Lana Norris who manage all of the logistical aspects of our laboratory, without whom we would all be lost. I have been fortunate to overlap with many wonderful graduate students and post-doctorates. They all make the lab a supportive environment, and I have learned so much from all of them, both in science and life. A special note of thanks to Adrian Jacobo, Anna Erzberger, Agnik Dasgupta, Brian Fabella, and Tobi Bartsch, who have all helped me with great advice, collaborative efforts, or educating me in any number of topics.
In the last year of work, I was blessed with the presence of German medical student Theresa Alisch. Prior to joining, she hadn’t so much as touched a pipette. The transformation she underwent during her time here into a thoughtful, capable, and rigorous scientist is one my favorite aspects of my time in the group. She was highly motivated, read broadly even when it was difficult, and made significant contributions to the project, both in raw effort, and with intellectual insights. The science, our group, and I immensely benefited from her time in the lab.

When I joined the laboratory, I was trained by Dr. Ksenia Gnedeva in many of the techniques I would eventually need, and she also conceived the original experiments that begin this project. I simply would not have gotten to this point without her. Our time was initially cut short when she had to transfer to the University of Southern California, but thankfully our work led us back together in a collaborative effort, which has proven educational for me and invaluable for our project. Ksenia has become a true mentor to me, and future students in her incipient laboratory will be in great hands.

It is tough to summarize how ideal a mentor Dr. Jim Hudspeth has been to me. His door is always open for scientific discussion, showing new data, or chatting about the state of our world. Dr. Hudspeth treats all members of the community with respect and kindness, and his generous and thoughtful demeanor trickle down through the lab, ultimately setting the tone, and are a large part of why the group members are all happy to be there. His inter-disciplinary approaches are a result of his breadth of expertise, and an invaluable part of the experience in this group. He has set an example for me of the type of scientist I aspire to be one day.
Finally, I have been supported by friends and family through my time in graduate school and before. Without them I wouldn’t be who I am today. In particular, my parents have supported me through all my endeavors, wise and otherwise, loved me unconditionally, and only ever expected of my brothers and I to do our best and to do good—something I aspire to every day still. Thank you for everything.
# Table of Contents

Acknowledgements ........................................................................................................... iv  
List of Figures ................................................................................................................... ix  
List of Tables .................................................................................................................... x  
Chapter 1: Introduction ....................................................................................................... 1  
1.1: The Mammalian Inner Ear ......................................................................................... 4  
1.2: Inner Ear Regeneration in Non-Mammalian Vertebrates ......................................... 7  
1.3: Lack of Inner Ear Regeneration in Mammals ........................................................... 10  
1.4: Approaches to Inducing Inner Ear Regeneration ...................................................... 12  
1.5: Hippo-Yap Signaling ............................................................................................... 14  
1.6: Identification of Activators of Yap Signaling .......................................................... 18  
Chapter 2: Methods .......................................................................................................... 19  
Chapter 3: Explant Studies on Screen Hits ........................................................................ 31  
3.1: Adult Murine Utricle Explants .................................................................................. 31  
3.2: Yap Dependence of TRULI-Mediated Proliferation ................................................. 40  
Chapter 4: Elucidation of TRULI’s Mechanism ............................................................... 41  
4.1: Initial Assessment of TRULI Mechanism ................................................................. 41  
4.2: ATP-competitive, Direct Inhibition of Lats1/2 ......................................................... 43  
Chapter 5: The Effects of TRULI in Other Contexts ....................................................... 48  
5.1: Cardiomyocyte Data ............................................................................................... 48  
5.2: Retina Organoid Data ............................................................................................. 49  
Chapter 6: Further Characterization of TRULI and its Derivatives ................................. 54  
6.1: In-Cell Potency ...................................................................................................... 55  
6.2: Data From Tri-Institutional Therapeutics Discovery Institute .................................. 55  
6.3: Medicinal Chemistry ............................................................................................. 59  
6.4: Lead Compounds ................................................................................................... 61  
Chapter 7: Discussion ...................................................................................................... 65  
7.1: Next Steps in the Inner Ear ..................................................................................... 66  
7.2: Other Organs .......................................................................................................... 68  
Appendix A: Manuscript ................................................................................................. 71  
References ....................................................................................................................... 126
List of Figures

Chapter 1: Introduction
Figure 1.1: Overview of the inner ear ........................................................... 3
Figure 1.2: Hair bundles activate in response to unipolar movement .......... 5
Figure 1.3: Hair cell regeneration in non-mammalian vertebrates .......... 9
Figure 1.4: The Hippo Pathway ................................................................. 17

Chapter 3: Explant Studies on Screen Hits
Figure 3.1: TRULI drives Yap nuclearization ............................................. 33
Figure 3.2: TRULI drives supporting cell proliferation ............................... 35
Figure 3.3: XMU-MP-1 fails to activate Yap ............................................... 37
Figure 3.4: XMU-MP-1 fails to drive supporting cell proliferation .......... 39

Chapter 4: Elucidation of TRULI’s Mechanism
Figure 4.1: TRULI prevents Lats-mediated Yap phosphorylation in confluent MCF10 cells ................................................................. 42
Figure 4.2: TRULI prevents Lats-mediated Yap phosphorylation in serum-starved HEK293A cells ................................................................. 44
Figure 4.3: TRULI is an ATP-competitive inhibitor of the Lats Kinases ........ 46

Chapter 5: The Effects of TRULI in Other Contexts
Figure 5.1: TRULI activates Yap in neonatal murine cardiomyocytes, driving proliferation ................................................................. 51
Figure 5.2: TRULI activates Yap in human retinal organoids, driving proliferation .... 53

Chapter 6: Further Characterization of TRULI and its Derivatives
Figure 6.1: In-cell determination of TRULI potency ................................. 56
Figure 6.2: Medicinal chemistry approaches ............................................. 60
Figure 6.3: Increased potency of derivatives ......................................... 62
Figure 6.4: Decreased response latency in derivatives ............................ 63
List of Tables

Chapter 6: Further Characterization of TRULI and its Derivatives

Table 6.1: Specificity of TRULI in binding and function ........................................58
Table 6.2: Derivatives of TRULI .............................................................................64
Chapter 1

Introduction

Hearing and balance disorders plague hundreds of millions of people across the world. The World Health Organization estimates 466 million people, or 6.1 % of the world's population, live with disabling hearing loss. In the United States, vestibular dysfunction has been reported in 35 % of individuals over the age of 40. The affected organs lie within the inner ear, which comprises six patches of sensory epithelia—five of which are dedicated to the detection of linear and rotational acceleration; the sixth, the cochlea, decodes complex sounds waves into neural signals, enabling hearing (Fig 1.1A).

Because these organs lack any regenerative capability, damage accumulates over a lifetime, leading to the ubiquitous problems. Moreover, no therapeutic approach has been established for these pathologies, so our best solutions thus far involve preventative measures, coping strategies, and hearing aids. Over the last few decades, some barriers to mammalian inner-ear regeneration have been elucidated through investigations into inner ear development and the regeneration of their homologous organs in non-mammalian vertebrates. Yet much remains to be understood before we can develop successful therapies.
Figure 1.1 Overview of the inner ear. (A) The inner ear comprises six patches of sensory epithelia encased in a fluid-filled bony labyrinth and is located within the temporal bone. (B) The utricle and saccule lie orthogonal to each other, allowing for detection of linear acceleration in all directions. (C) The utricle and saccule have two polarities of hair cells (red) that reverse around the midline and are arrayed in a hexagonal pattern among supporting cells (green). The hair bundles are loaded by otoliths, crystals of calcium carbonate. (D) The ampullae of the three semi-circular canals bear hair cells (red) of a single polarity, and their hair bundles protrude into a gelatinous mass termed the cupula (yellow). (E) The organ of Corti lies along a tapered basal membrane that increases in width from the base of the cochlea to its apex. Inner hair cells (red) play a role in amplifying and sharpening the signal. Outer hair cells (red) transmit electrical signals to the central nervous system. Inner hair cells (red) transmit electrical signals to the central nervous system. The organ of Corti has several types of supporting cells, defined by their location and function. Image in (A) was adapted from Retzius, G. Das Gehörorgan der Wirbeltiere. II. Das Gehörorgan der Reptilien, der Vögel und der Säugethiere.
Section 1.1: *The Mammalian Inner Ear*

The sensory epithelia of all mammalian hearing and vestibular organs derive from the otic placode—the anlagen of the inner ear—and thus share two cell types: supporting cells, which play a homeostatic and architectural role, and mechanosensitive hair cells, with their eponymous apical tufts of stereociliary bundles arranged in tightly packed rows of increasing height. Tip links, proteinaceous strings, connect the tips of adjacent stereocilia: at its upper edge, each tip link is attached through a series of transmembrane complexes to myosin motors, that mediate fast adaptation. At its lower end, a tip link is thought to be connected to ion channels, so thus stretching of the tip links opens the channels, depolarizing the cell (Fig. 1.2). The orientation of stereociliary rows, in conjunction with their tip link attachments, allows for their coordinated movement and directional specificity, for deflection in one direction opens ion channels, causing depolarization, and deflection in the opposite direction reduces the number of open channels, yielding hyperpolarization.

The sensory epithelia of the inner ear are arranged in distinct and precise geometrical patterns that are critical to their functions. All hair cells of the utricle and saccule, the organs responsible for the detection of linear acceleration, are either oriented towards or away from the line of reversal roughly at the midline, and are arrayed in a hexagonal pattern among supporting cells, which in these organs are considered a uniform type. The tips of the stereocilia are loaded by otoconia, clusters of calcium carbonate crystals that provide the mass for inertia-mediated activation (Fig. 1.1B,C). The hair bundles in each of the three ampulae of the semi-circular canal, the
Figure 1.21 Hair bundles activate in response to unipolar movement. The stereocilia of hair cells are arranged in rows of increasing height, with tip links connecting the tops of each. The lower end of the tip links is embedded in ion channels, so when the bundles are deflected towards their tall edge the tip links stretch, opening the channels allowing divalent ions to flow through and depolarize the hair cells. Deflection in the opposite direction causes hyperpolarization, and deflection orthogonal to the apical surface of the hair cell has no effect.
organs responsible for detecting rotational acceleration, are all oriented in a common
direction. The long hair bundles are embedded in a gelatinous mass, called the cupula,
that deflects upon inertial movement of the endolymph within the canals (Fig. 1.1D).
Again the result is depolarization for motion in one direction and hyperpolarization in the
other.⁴

The cochlea, the organ that processes sound, has the most geometrically
intricate organization. The sensory portion of the cochlea, known as the organ of Corti,
lies upon a basilar membrane of tapering width from the base to the apex, a key
component of its tonotopic gradient. The tunnel of Corti separates the two types of
cochlear hair cells, all of which have their bundles’ short rows medially and tall rows
laterally. These receptors lie among several classes of supporting cells, defined by their
architectural as well as functional roles. Lateral to the tunnel are three parallel rows of
outer hair cells, which are innervated primarily by efferent nerves, and play a role in
amplification and frequency resolution through an active process. These cells display
both depolarization-dependent cytoskeletal contraction and active motion of their
bundles. In contrast, inner hair cells, medial to the tunnel, are innervated by afferent
nerves and thus propagate responses to the central nervous system (Fig. 1.1E)⁵.
Section 1.2: Inner Ear Regeneration in Non-Mammalian Vertebrates

Hair cell-based organs in several non-mammalian vertebrates regenerate throughout their lifetimes. Two models of note are the avian cochlea (basilar papilla) and the zebrafish lateral line. The latter, which comprises small patches of hair cells and supporting cells—the neuromasts—distributed longitudinally across the surface of the body, measures motion of the surrounding fluid for both during normal movement and in the presence of prey or predators. As in the mammalian utricle and saccule, equal numbers of hair cells face in the rostral and caudal directions, permitting bi-directional sensitivity. Studies of these organs in development and regeneration have shed much light on the high-level processes, as well as the common and the distinct pathways involved.

The regenerative process in the avian cochlea involves two phases. An early wave of transdifferentiation, or direct conversion of supporting cells into hair cells, yields some new hair cells at the cost of supporting cells. To further enable regeneration, supporting cells adjacent to the site of damage undergo proliferation, yielding daughter cells that can either differentiate into hair cells or remain supporting cells, thus preserving the ratio of the cell types (Fig. 1.3A)\textsuperscript{6}. After damage, supporting cells in the zebrafish neuromasts always undergo division before generating two new, oppositely oriented hair cells, thereby conserving the balance of vector sensitivity. Supporting cells also divide symmetrically to replenish their own number (Fig. 1.3B)\textsuperscript{7}.

From these studies and others, it has become clear that the two key processes involved are transdifferentiation and proliferation of supporting cells. Various classical
Hair cell regeneration in non-mammalian vertebrates. (A) In the avian cochlea (basilar papilla) hair cells regenerate throughout the organism’s lifespan. This process involves two main programs: (1) an early wave of transdifferentiation, direct conversion of adjacent supporting cells into hair cells; (2/3) proliferation of supporting cells, either symmetrically, replenishing the supporting cell population, or asymmetrically, yielding one daughter hair cell and one supporting cell. (B) The neuromast of zebrafish is surrounded by mantle cells (purple) and have hair cells (red) of two polarities arrayed amongst supporting cells (green). When hair cells die, a nearby supporting cell undergoes division, yielding two hair cells of opposite polarity. Supporting cells also undergo division to replenish the supporting cell population.
signaling paradigms underpin each. Both in development and regeneration, transdifferentiation is mediated primarily through canonical Notch signaling, an ancient short-range communication system. This process culminates in the activation of transcription factors that are necessary for hair cell differentiation, such as Atoh1 and Pou4F3. Several pathways have been implicated in control of supporting cell proliferation during regeneration, including Fgf, Wnt, Egf, and Igf signaling⁴,⁸.

Section 1.3: Lack of Inner Ear Regeneration in Mammals

In contrast to the lifelong regenerative capacity of non-mammalian vertebrates, functional hair cell regeneration is largely absent in mammals. In the adult mammalian utricle, it has been shown that a modest number of hair cells regenerates after total ablation. However, the new hair cells are predominantly the result of transdifferentiation, and it is unclear whether there is any significant functional recovery. Although this is a meager response, it lies in stark contrast to the total inability of the mammalian cochlea to yield any regenerative response⁴.

One typical explanation for why the mammalian cochlea does not regenerate is that, in contrast to its regenerative homologues, it has a drastically more complex architecture, thought to enable our higher range of frequency detection⁸. This reasoning applies less well to the vestibular organs, which are more similar in their organization to the avian cochlea and zebrafish neuromast. It has been argued that in the vestibular system, proliferation of supporting cells is impeded by rings of F-actin and E-cadherin junctions that accumulate around the cells as the organ ages⁹; this does not occur in the
regenerative systems. These observations might equally represent a down-stream effect due to a dearth of proliferation, however and not a primary cause. No functional evidence has been generated in support of this hypothesis.

More is known about the molecular roadblocks preventing regeneration. In the cochlea, transdifferentiation is completely absent after damage. In the regenerative homologues, it is known that Notch-mediated signaling plays a key role. However, in the adult mammalian cochlea, Notch-responsive genes are expressed at very low levels, and although some components are upregulated after damage, Notch inhibition in this context fails to drive significant generation of new hair cells. It is unknown how the Notch responsiveness of these supporting cells is kept low\textsuperscript{8,10}. In the adult mammalian utricle new hair cells can arise by transdifferentiation throughout an organism’s lifespan, although it is unclear how robust the physiological recovery is. In accord with the utricle’s slightly stronger regenerative capacity, activation of Notch signaling in supporting cells after hair cell ablation upregulates \textit{Atoh1} expression, an early marker of hair cell differentiation, and a subset of the cells express \textit{Myo7a}, a marker of mature hair cells\textsuperscript{4}.

Because it is thought that cell division is a key limiting step in the regenerative response, anti-proliferative programs have also been an area of intense focus. Wnt signaling has been shown to drive supporting cell proliferation in both the developing utricle and cochlea. However, both organs become refractory to Wnt activation as they age. Several of the cyclin-dependent kinase inhibitors (CDKIs) have also been shown to play critical roles in maintaining the post-mitotic status of the cochlea: p19Ink4d,
p21Cip1, p27Kip1, Rb1, and Rbl2. In the utricle, Rb1 has been demonstrated to impede proliferation, but p19Ink4d and p21Cip1 appear to play no role\textsuperscript{4,8,10}.

Section 1.4: Approaches to Inducing Inner Ear Regeneration

The insights from the investigations highlighted above have directed researchers into two main avenues of inducing hair cell regeneration. The first, and more thoroughly studied goal, is that of inducing supporting cell transdifferentiation. Although much more remains to be investigated, several approaches have demonstrated its potential, as well as its limitations. The second goal, driving supporting cell proliferation, is thought to be a key limitation on regeneration, given the natural evidence of its import in bird and zebrafish homologues, as well as the poor results to date of using only transdifferentiation to drive hair cell regeneration in mammalian systems.

Because hair cell differentiation across these many systems, during both development and regeneration, is Notch-mediated, many groups have utilized gamma-secretase inhibitors in attempts to augment this process in the adult mammalian systems. Within a few days after birth, the cochlea down-regulates its Notch ligands and becomes insensitive to inhibition. However, although there is not complete consensus, some groups report that after damage, the cochlea can upregulate some of the Notch program. In support of this hypothesis, gamma-secretase inhibition applied to noise-damaged mice increased the number of outer hair cells, but only at the base of the cochlea. Although there was a notable, but small, physiological recovery at the lowest frequencies, the overall recovery was minimal at best. Application of a different gamma-
secretase inhibitor after damage led to ectopic hair cells in guinea pigs. No significant physiological recovery was appreciated\textsuperscript{10}.

Because Notch signaling is still active in the adult vestibular system, the utricle can form more hair cells after gamma-secretase treatment \textit{in vitro}. The preponderance of this work has been done in explant culture systems and varies in details of the results: how many new hair cells, the extent of their maturation, and what region of the utricle are new hair cells found. Moreover, no one has yet demonstrated physiological recovery \textit{in vivo} with this approach\textsuperscript{4}.

The other major approach taken for inducing transdifferentiation is to over-express Atoh1, a transcription factor necessary for—and somewhat sufficient— for the induction of hair cell formation. In the utricle, virally mediated and transgenic approaches have been employed, but yielded different results. Adenovirus-mediated gene delivery improved hair cell regeneration in damaged vestibular organs from adult rodents; however, physiological recovery was small to absent. The transgenic approach failed to drive formation of any new hair cells in the adult. In the cochlea, Atoh1 over-expression, either virally or through transgenics, failed to yield new hair cells\textsuperscript{10}.

Several programs, including Wnt signaling and numerous growth factors, have been shown to augment proliferation during development, but sensitivity to these perturbations is lost only a few days after birth in both the utricle and the cochlea\textsuperscript{4,10}. In the utricle, a more drastic measure, over expressing the oncogene N-Myc, did yield supporting cell proliferation in adult utricle explants \textit{in vitro}, but all of the cells failed to progress through G2 or underwent apoptosis after completion of the cell cycle\textsuperscript{11}. Our
group found that the pioneer transcription factors Sox4 and Sox11 are key in the proliferation of utricle supporting cell during development; moreover, virally mediated over-expression in adult explants induced supporting cell proliferation, and a subset of the resultant cells then differentiated into hair cells\textsuperscript{12}. No approaches have been demonstrated to induce supporting cell proliferation in the cochlea.

**Section 1.5: Hippo-Yap Signaling**

A former member of our group, Dr. Ksenia Gnedeva, demonstrated that the Hippo pathway limits the size of the developing murine utricle, and that the pathway’s down-stream target, the Yap-Tead complex is active during—and necessary for—proliferative regeneration in the neonatal utricle\textsuperscript{13}. These observations suggested that activation of Yap signaling could engender supporting-cell proliferation in adult tissue.

In view of its fundamental roles in development, proliferation, stem-cell maintenance, and de-differentiation, Hippo signaling is an inviting target for driving regeneration\textsuperscript{14,15}. The canonical Hippo pathway is an ancient and highly conserved signal-transduction cascade that comprises two pairs of core kinases. When proliferation is inappropriate, Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn phosphorylate the transcriptional co-activator Yap and its homolog Taz, which as a result are sequestered and degraded in the cytoplasm. When the pathway is inactive, Yap enters the nucleus, interacts with transcription factors of the Tead family, and initiates cell division\textsuperscript{16}. Yap signaling integrates a variety of information from the cellular environment, including biomechanical cues, cell adhesion, cell density, cell polarity, metabolic
challenges, and signals such as Notch, Wnt, and several GPCR-mediated pathways. The Hippo cascade is the conduit through which much, but not all, of this information is integrated into a decision regarding Yap activation\textsuperscript{17} (Fig. 1.4).

Yap activity has been shown to play a role in the mammalian organs which can regenerate, such as the liver, lung, intestine, and skin\textsuperscript{14}. Furthermore, increasing Yap activation in these contexts augments the regenerative response \textit{in vivo}. Of greater interest, Yap activation has also been shown to drive regeneration in non-mitotic tissues such as the heart and retina. After induction of myocardial infarction in adult mice, treatment with agrin, a secreted protein that activates Yap specifically in that context through the Dag1 receptor, can cause proliferation of adult mouse cardiomyocytes \textit{in vivo}. One month later the ejection fraction of treated mice was identical to that of undamaged mice\textsuperscript{18}. In retinal tissue, transgenic overexpression of a constitutively active form of Yap in Müller cells, precursors of photoreceptors, drives cell cycle re-entry, a key missing step in mammalian retinal regeneration\textsuperscript{19,20}.

Despite the evidence that Yap reactivation offers a uniquely powerful approach for tissue regeneration, the techniques involved are cumbersome, indirect, or context-specific\textsuperscript{21}. Transgenic manipulation, viral induction, and GPCR-mediated Yap activation lack translational value, so due to these shortcomings of available tools, we conducted a screen for small-molecule activators of Yap. With such a compound, we hoped to test our original hypothesis that Yap activation in supporting cells of the adult utricle would foster mitotic hair cell regeneration.
The Hippo Pathway. (A) The core of the Hippo pathway comprises two pairs of kinases, MST1/2 and LATS1/2, each with co-activators, Sav1 and Mob1 respectively. Despite the relative simplicity of the cascade, there is no specific ligand and receptor, but instead numerous inputs (“Hippo Regulators”) impinge upon the cascade at various entry points, yielding an integrative decision regarding Yap activation. When active, the cascade culminates in the phosphorylation of Yap at multiple sites, yielding sequestration and degradation of the protein. When the cascade is inactive, Yap remains unmodified and is free to translocate to the nucleus, where it binds primarily to members of the Tead family, driving its transcriptomic programs. Small molecules known to modify the Hippo pathway, and their modes of action, are indicated in red.
Hippo Regulators

Mechanical Forces
Cell Polarity
GPCRs
Energy Stress
Cell Junctions
Growth Factors
Wnt Signaling
Notch Signaling

Hippo Regulators

MAP4Ks
TAO1/2/3

MST1/2
SAV1
MOB1

LATS1/2

XMU-MP1
TRULI

YAP

Sequestration

14-3-3

P

YAP

β-TrCP

P

YAP

Verteporfin

Cytoplasm

Nucleus

TEAD1-4

Downstream Programs
Cell Cycle
Migration
Plasticity
Cell Survival
Cytoskeletal Morphology
Section 1.6: Identification of Activators of Yap Signaling

In some monolayer epithelial cultures, increased cell density leads to cytoplasmic retention and degradation of Yap protein, a process reminiscent of the molecular mechanism downstream of Hippo-driven growth restriction during normal development\textsuperscript{22,23,24}. To seek inhibitors of this process, former members of our group designed a high-throughput phenotypic screen for compounds that promote nuclear Yap translocation in confluent human cell cultures. After testing three lines, they chose MCF 10A mammary epithelial cells, which demonstrated robust negative correlation between cellular confluence and the fraction of cells with nuclear Yap.

For the small-molecule screen, MCF 10A cells were seeded to achieve dense cultures in 384-well plates. A single compound was deposited in each well at a concentration of 10 \( \mu \text{M} \). Every plate also included a positive control, sub-confluent cells, and a negative control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a concentration equivalent to that in which the compounds were applied. After 24 hr incubation, the investigators determined the fraction of the cells with nuclear Yap and compared that value to the median negative-control value. They also scored the total number of cells in each well and eliminated toxic substances that decreased the number by more than one standard deviation in comparison to the dense control cultures. Nontoxic compounds that increased nuclear Yap by more than one standard deviation in comparison to the negative control were scored as hits. Owing to the robustness of contact inhibition in the dense cell cultures, only six of the 140,238 compounds screened met these criteria and were validated in the secondary screen\textsuperscript{25}.  

18
Chapter 2

Methods

Animal care and strains

Experiments were conducted in accordance with the policies of the Institutional Animal Care and Use Committees of The Rockefeller University, the University of Southern California, and the Weizmann Institute of Science.

Swiss Webster mice were obtained from Charles River Laboratories. $Sox2-Cre^{ER}$, $\alpha$MHC-Cre, and $ROSA26-tdTomato$ mice were obtained from the Jackson laboratory. $Yap^{fl/fl}$ were provided by Dr. Martin, Baylor College of Medicine.

Chemical libraries

A total of 140,238 different compounds from a library at The Rockefeller University High-Throughput and Spectroscopy Resource Center were chosen by a quantitative estimate of drug-likeness score\textsuperscript{26}. The compounds originated in the following commercially available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth Junction, NJ), BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego, CA), Specs (Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and AMRI (Albany, NY). Compound stocks were stored in 384-well polypropylene plates at a final concentration of 5 mM in DMSO at -30 °C.
High-throughput screen for small-molecule activators of nuclear Yap

Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T), and two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested for the screen. Of the three lines, only MCF 10A cells display a reproducible correlation between the number of cells seeded and the number of cells adhered after 24h in culture and thus were selected for the screen.

MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor (Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin (Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution. Cell cultures reached 100 % confluence at an approximate density of $3 \times 10^5$ cells per square millimeter.

For the small-molecule screen, chemical-library plates were thawed at room temperature and 0.1 μL of each compound was placed in a well of a 384-well assay plates (Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer Janus with Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture medium to achieve a final concentration of 10 μM for each compound and 0.25 % (vol/vol; 35 mM) dimethyl sulfoxide. Negative (100 % confluent) and positive (25 % confluent) control wells included an identical concentration of the DMSO vehicle.

After 24 hr incubation, the cells were fixed, washed thrice in PBS, and immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). 10X objective lens on the ImageXpress XLS
wide-field Micro reader (Molecular Devices, Sunnyvale, CA) with MetaXpress software (Molecular Devices) were used to automatically image the plates. Using an empty plate to avoid out-of-focus images, we configured a laser-based autofocus routine for automatic well-bottom detection. We imaged DAPI and Yap conjugated to Alexa Fluor 488 with filter cubes for respectively DAPI (excitation, 350-400 nm; emission 415-480 nm) and FITC (excitation, 460-505 nm; emission, 510-565 nm). The acquisition system was configured to image one site per well. After the fluorescence of DAPI had been used to set the image-based autofocus, the exposure time for each fluorophore was determined with a negative-control well in which the fluorescence signal was set to 75% of the camera’s maximal intensity.

An image-segmentation application from MetaXpress software was used to automatically analyze the images. The number of cells was estimated by selecting an average size and intensity level above the local background in the DAPI channel.

A built-in translocation module that measured the intensity movement from one compartment to another was configured to determine the nuclear or cytoplasmic status of the Yap. These measurements were acquired first for the positive and negative control wells to determine an arbitrary threshold for the intensity ratio that characterized nuclear translocation versus cytoplasmic retardation of Yap. The same threshold was then applied to each well treated with a small-molecule to identify the substances that increased the number of cells with nuclear Yap without affecting cell survival. Positive controls were not used to normalize data, but to confirm whether the cells were healthy and behaving as expected.
Images were stored in the MDCStore database and analyzed using MetaXpress software (Molecular Devices). Output data were uploaded and analyzed using the CDD Vault from Collaborative Drug Discovery (Burlingame, CA).

The compounds showing over 10% Yap nuclear translocation and over 5,000 cells per field were selected and the corresponding images were checked to verify the phenotype. To determine half-maximal inhibitory concentrations, the selected compounds were re-tested in concentration-response experiments by serially diluting by half for a total of ten dilutions to achieve assay concentrations ranging from 20 µM to 0.03 µM. IC₅₀ values were calculated by CDD software. Six compounds were confirmed in this secondary screen.

**Small-molecule Lats inhibitor**

The compound N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and herein termed TRULI, was obtained from Enamine LLC (Monmouth Junction, NJ; catalog number Z730688380).

**Dissection and culture of inner-ear sensory epithelia**

Internal ears were dissected from mice euthanized with fluothane and placed into ice-cold Hank’s balanced salt solution (HBSS; Gibco14025-092)¹².

Unless indicated otherwise, explanted cultures of the utricle and cochlea were maintained in an incubator at 37 °C in the presence of 5% CO₂ and 95% O₂.
complete growth medium comprised Dulbecco's modified Eagle medium with nutrient mixture F-12 (DMEM/F12) supplemented with 33 mM D-glucose (Sigma G8644), 19 mM NaHCO₃ (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine (Sigma G8540), 5 mM nicotinamide (Sigma N0636), 40 µg/L epidermal growth factor (Sigma E9644), 20 µg/L fibroblast growth factor (Sigma F5392), insulin-transferrin-selenite solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco 15240062).

For proliferation assays, utricles were cultured with 10 µM 5-ethynyl-2′-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit, Thermo C10340).

**Culture of epithelial cells**

MCF 10A cells were cultured as described above. HEK293A cells were maintained in DMEM (Gibco 11965-092), 10 % fetal bovine serum (Sigma F2442), and antibiotic-antimycotic solution. All cells were incubated at 37 °C in the presence of 5 % CO₂ and 95 % O₂.

**Culture of primary cardiomyocytes**

Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by intercrossing αMHC-cre mice²⁷, which exhibit highly efficiency recombination in cardiomyocytes, with ROSA26-tdTomato mice²⁸ that require Cre-mediated recombination for expression. Both lines were maintained on a C57BL/6 background.
Neonatal primary cardiac cultures were isolated from P0 (first postnatal day) pups with a neonatal dissociation kit (Miltenyi Biotec, 130-098-373) and homogenizer (gentleMACS). Cardiac cultures were seeded in gelatin-coated wells coated with 0.1 % gelatin (G1393, Sigma) in DMEM/F12 medium supplemented with 1% L-glutamine, 1 % sodium pyruvate, 1 % nonessential amino acids, 1 % penicillin-streptomycin solution, 5 % horse serum, and 10 % fetal bovine serum. After culture in 5 % CO₂ for 24 hr at 37 °C, the medium was replaced for an additional 72 hr with bovine serum-free medium containing 0.1 % (vol/vol) DMSO and, for experimental samples, 20 μM TRULI.

**Culture of human pluripotent stem cells and retinal organoid**

The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical Research, Camden, NJ) was maintained using standard methods. Human retinal organoids were produced from these cells²⁹. In three independent proliferation assays, five organoids per experimental condition were sampled after 225-280 d in culture. The organoids used in the immunoiblot analysis were cultured for 160-178 d.

**Immunohistochemistry of murine inner-ear sensory epithelia**

Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA; Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 % Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358).
The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A (Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied overnight at 4 °C. Samples were washed with phosphate-buffered saline solution supplemented with 0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled secondary antisera (Life Technologies) were applied in the same solution for 1 hr at room temperature. Nuclei were stained with 3 mM DAPI.

**Immunofluorescence assays for cardiomyocytes**

Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature, permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled overnight at 4 °C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope.

**Immunofluorescence imaging of retinal organoids**

Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9
(1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed three times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in the serum solution were added for 1 hr at room temperature followed by two washes with PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa Fluor 555 C10338) was followed by a wash with PBS. After incubation with DAPI (1:10,000 in PBS) for 5 min and the application of mounting solution, sections were imaged by confocal microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA objective lens with a pinhole size set at the first Airy disc.

**Protein immunoblotting and quantification**

MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice between sonications. After lysates had been scraped and centrifuged at 10,000 RPM for 10 min at 4 °C, the supernatants were immediately subjected to electrophoresis or stored at -80 °C.

A standard immunoblotting protocol was used with the following specifications. A 4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156) and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies had been reconstituted in the same solution, the membrane was incubated overnight at
4 °C. After three 5 min washes at room temperature in tris-buffered saline solution with 0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase (Millipore) was applied in the same solution for 1 hr at room temperature before activity was detected (SuperSignal West Pico PLUS, Thermo 34580). Images were acquired with an iBrightFL1000 system.

We used at a dilution of 1:1000 primary antibodies directed against Yap (sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565), phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730), phospho-Mob1 T35 (CST 8699), tubulin (Sigma T6793), and GAPDH (Abcam ab8245).

Cultured cardiomyocytes were lysed using RIPA supplemented with protease and phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of each sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and subsequently transferred to a PVDF membrane. Following 1 hr blocking at room temperature, membranes were incubated with the following antibodies against phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358, Novus) and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room temperature. Following two washes in tris-buffered saline solution containing 0.1 % Tween 20, membranes were incubated with horseradish peroxidase anti-rabbit or secondary antibodies (Jackson). The signal was detected by super-signal west pico plus chemiluminescence kit (34580, Thermo-Fisher).

Immunoblots were quantified through measurement of band intensity with Fiji. The final value of each band’s intensity was normalized by the sum of all the bands’
intensities. Significances from one-sided Student’s t-tests are denoted as follows: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

**Imaging of Yap nuclearization and quantification of proliferation**

Confocal imaging was conducted with a confocal microscope enhanced with structured illumination (VT-iSIM, VisiTech International Ltd.).

For quantification of Yap nuclearization, for each condition two fields of supporting cells were imaged at 60X from two utricles. Using CellProlifer\textsuperscript{31}, we masked Sall2-positive nuclei and measured the intensity of their labeling. The same mask was then applied to the Yap channel and the intensity of labeling was measured. The ratio of the Yap to the Sall2 intensity was calculated for each condition in 680 cells after TRULI treatment and 570 cells for DMSO controls.

For quantifying the proliferation of supporting cells, we imaged utricles at 60X, then assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The maximal values in z-stacks were projected to display the entire supporting-cell layer of the sensory epithelium, excluding connective tissue and the surrounding epithelium. Using CellProlifer\textsuperscript{31}, we counted the number of EdU-positive nuclei. Alternatively, EdU- and Sox2-doubly positive nuclei were counted using Multi-point Tool in ImageJ.

Images acquired from neonatal cardiac cultures were analyzed using ImageJ software by thresholding for cardiomyocytes according to endogenous tdTomato fluorescence. Thresholded figures were carefully and manually separated by fine lines
to de-cluster cells in case they touch, basing on original images, following by measurements of area and solidity.

Images acquired from retina organoids were analyzed with CellProfiler\textsuperscript{31}. Masks were created for all the Sox9-positive nuclei, and the percentage of EdU- and Sox9-positive nuclei were counted.

\textit{In vitro kinase assay}

The \textit{in vitro} kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized to the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2 (Carna 01-124). Reactions were conducted with 10 $\mu$M STK1 substrate and 10 $\mu$M ATP, unless otherwise indicated. For the ATP-shift assay, ATP was also used at concentrations of 50 $\mu$M and 250 $\mu$M. Lats1 was employed at a concentration of 200 pg/$\mu$L and Lats2 at 50 pg/$\mu$L, unless otherwise indicated. For the assay in which Michaelis-Menten constants for ATP were determined, each enzyme was at a concentration of 62.5 pg/µL, and Lats1 ran for 30 min, and the Lats2 ran for 20 min, all at room temperature. The DMSO concentration was maintained at 0.5 \% (vol/vol) throughout all experiments, and a Janus 384 MDT (PerkinElmer) equipped with a 50 nL Pintool (V&P Scientific, Inc.) was used to add the compounds dissolved in DMSO to the reaction. The enzyme, substrate, ATP, and TRULI were combined in a low-volume 384-well plate and shaken for 50 min at room temperature, unless otherwise indicated. The reaction was stopped by adding the detection reagents, which were prepared at an 8:1
biotin:streptavidin ratio, and shaken for 60 min at room temperature. All reactions were conducted in triplicate and a Synergy NEO (Biotek) was used to detect the signal.

**Cellular kinase assay**

HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 cells per well in the medium described above. To start the assay, new serum-free medium with various concentrations of the compound was added to the cells, which were then incubated for 30 min at 37 °C. The DMSO concentration was kept at 0.1 % (vol/vol), and all experiments were performed in triplicate.

Total Yap and phospho-Yap were detected according to the two-plate protocol for adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127] Cellular Kit, Cisbio 64YapPEG). The signal was detected by Synergy NEO (Biotek).
Chapter 3

Explant Studies on Screen Hits

Having found the six validated hits in the primary screen, we turned to our model system of interest, adult murine utricle explants, to test our original hypothesis that Yap activation could drive supporting cell proliferation. I assayed the hits at various concentrations and times, using immunohistochemistry to assess Yap activation and ensuing proliferation. During our screen XMU-MP-1, an inhibitor of the Mst1/2 kinases, was published, so we included it in our analysis as well. Ultimately, of the seven compounds tested, only one, RU-5757, demonstrated all the characteristics of interest.

Section 3.1: Adult Murine Utricle Explants

RU-5757, or N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, drove robust Yap nuclear translocation after 24 hr of treatment at a concentration of 10 μM (Fig. 3.1) and caused a striking reduction in the level of Yap phosphorylation. After 5 d of treatment, this substance evoked robust re-entry into the cell cycle of adult utricular supporting cells (Fig. 3.2). For the sake of brevity we term this substance "TRULI."

Although XMU-MP-1 modestly reduced the amount of phospho-Yap, it decreased the total Yap by a greater amount so that the ratio of phospho-Yap:total Yap actually increased (Fig. 3.3). No significant proliferation was observed after 5 d of treatment (Fig. 3.4).
Figure 3.1 | **TRULI drives Yap nuclearization**. (A) Immunohistochemistry demonstrates that TRULI exposure drives Yap, yellow, into the nuclei of utricular supporting cells. Sall2, green, is a nuclear marker of supporting cells. (B) The nuclear localization of Yap is quantified as a ratio to the constitutively expressed protein Sall2 ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 570$ control nuclei and 680 treated nuclei).
Figure 3.2I **TRULI drives supporting cell proliferation.** (A) *In vitro* exposure to TRULI for 5 d elicits proliferation of supporting cells, as measured by the incorporation of EdU. Verteporfin, an inhibitor of the Yap-Tead interaction, drastically reduces this effect. (B) The number of EdU-positive cells per utricle increases with TRULI ($p = 0.021$ by an unpaired, one-tailed $t$-test, control $n = 2$, TRULI $n = 3$), but the effect is blocked by verteporfin ($p = 0.028$ by an unpaired, one-tailed $t$-test, $n = 2$).
A

Control

TRULI

TRULI; VP

B

EdU-positive cells per utricle

Control  TRULI  TRULI; VPertoporfin

* *
Figure 3.3I **XMU-MP-1 fails to activate Yap.** (A) Six utricles per condition were treated for 24 hr with 10 µM TRULI or XMU-MP-1 to assess effects on the amount of phospho-Yap by comparison to control conditions. (B) Quantification of band-intensity ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that XMU-MP-1 does not reduce the fraction of phosphorylated Yap.
A

Control | TRULI | XMU-MP-1

pYap

tYap

Tubulin

B

Control | TRULI | XMU-MP-1

pYap/Tubulin

pYap/Tubulin

0.0 | 0.5 | 1.0 | 1.5 | 2.0

0.0 | 0.5 | 1.0 | 1.5 | 2.0
Figure 3.4| **XMU-MP-1 fails to drive supporting cell proliferation.** When adult mouse utricles were explanted and cultured with EdU (white) and either TRULI or varying concentrations of XMU-MP-1 for 5 DIV, the latter caused no increase in proliferation. Nuclei are stained with DAPI (blue).
Section 3.2: Yap Dependence of TRULI-Mediated Proliferation

To test whether the proliferative effect of TRULI is exerted through Yap, we co-treated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between Yap or Taz and Tead transcription factors\textsuperscript{33}. Consistent with the hypothesis, co-treatment with verteporfin precluded a proliferative response (Fig. 3.2) To confirm these results, a collaborator at USC, Ksenia Gnedeva, used \textit{SOX2-Cre}\textsuperscript{ER} and \textit{Yap}^{fl/fl} mice to generate inducible conditional-knockout animals deficient for the protein in the sensory organs of the inner ear\textsuperscript{34,35}. Owing to the extensive lifetime of Yap protein\textsuperscript{36}, Cre-mediated recombination was induced either 7 d or 14 d prior to utricular explantation and culture. In the utricles isolated from \textit{Yap}^{fl/fl} littermate mice lacking Cre recombinase, treatment with TRULI elicited robust proliferation of supporting cells\textsuperscript{25}. In contrast, in utricles explanted from Yap knockout animals, proliferation was significantly reduced.
Chapter 4

*Elucidation of TRULI’s Mechanism*

Having demonstrated that TRULI drives Yap-mediated supporting cell proliferation in the adult murine utricle, we aimed to determine its mechanism of action. To this end, we employed two cell line models with distinct methods of activating Hippo signaling. Within these contexts we applied TRULI and found that in both, it interferes with the ability of Lats1/2 to phosphorylate Yap, either directly or indirectly. The structure of TRULI contains a hinge-binding motif indicative of ATP-pocket-binding mechanism of inhibition. To test this hypothesis, we developed an *in vitro* kinase assay (IVKA) to characterize the inhibitory potency of TRULI on Lats1/2. Together, these experiments demonstrate that TRULI is an ATP-competitive inhibitor of the Lats1/2 kinases.

**Section 4.1: Initial Assessment of TRULI Mechanism**

After treatment of confluent MCF10a cells with 10 μM of TRULI for 24 hr, protein blotting revealed that the Hippo signaling cascade was intact through the phosphorylation of the activation loops of Lats1 (S909) and Lats2 (S872) (Fig. 4.1). However, the phosphorylation of Yap at residue S127 was decreased, suggesting that TRULI is—directly or indirectly—an inhibitor of Lats kinases.

To confirm this inference we turned to HEK293A cells, which activate Lats kinases in response to serum starvation and thus inactivate Yap to prevent growth during nutrient
Figure 4.1 | **TRULI prevents Lats-mediated Yap phosphorylation in confluent MCF10a cells.** Protein immunoblotting discloses that 24hr treatment of MCF 10A cells with TRULI leaves Hippo signaling intact through the activation of Lats kinases, but that Yap phosphorylation is greatly diminished.
deprivation\textsuperscript{37,38}. We pre-treated 80% confluent HEK293A cells with 10 μM TRULI for 1 hr, followed by 30 min of serum starvation. In control cultures, starvation elicited robust phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127 (Fig. 4.2). In cultures pre-treated with TRULI, however, serum starvation failed to evoke phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed conditions, phospho-Yap levels were below those of serum-fed control cells. Negative-feedback regulation in response to elevated Yap activity might explain why the amount of Lats1 S909 was enhanced in the treated, serum-fed condition\textsuperscript{39}. These results together confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap.

Section 4.2: ATP-competitive, Direct Inhibition of Lats1/2

The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding motifs of ATP-competitive kinase inhibitors (Fig. 4.3A) Because there are no available crystal structures of the Lats kinases, collaborators at the Tri-Institutional Therapeutics Discovery Institute created a homology model from the crystal structure of the ATP pocket of similar kinase ROCK1 bound to a small-molecule inhibitor containing a 7-azaindole moiety. A putative structure of the complex between Lats1 and TRULI was then generated by molecular docking\textsuperscript{25}. Because the predicted protein-ligand contact residues of Lats1 and Lats2 are almost completely conserved, the model suggests that TRULI can bind either with similar inhibitory potencies.
Figure 4.2 | **TRULI prevents Lats-mediated Yap phosphorylation in serum-starved HEK293A cells.** Serum starvation of HEK293A cells in the presence of TRULI also demonstrates Lats activation but suppression of Yap phosphorylation.
Figure 4.3| **TRULI is an ATP-competitive inhibitor of the Lats kinases.** (A) TRULI comprises a thiazolimine backbone with two substituents: a benzyl group and a 7-azaindole hinge-binding motif. (B) An *in vitro* assay of Lats1 kinase activity shows that the *IC*$_{50}$ for TRULI increases with the ATP concentration, from 0.2 nM at 10 µM, to 4.3 nM at 50 µM, and to 80 nM at 250 µM, demonstrating that the compound is an ATP-competitive inhibitor. (C) The half-maximal inhibitory concentration of TRULI against Lats2 was *IC*$_{50}$ = 0.2 nM.
To test our speculations about the mechanism of TRULI inhibition, we optimized an *in vitro* kinase assay with truncated forms of Lats1 (residues 589-1130) and Lats2 (residues 553-1088) that include primarily the kinase domains. As a substrate we employed the peptide STK1, which is known to be phosphorylated by these enzymes\(^\text{40}\). Because we hypothesized TRULI was ATP-competitive, we first determined the Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 \(\mu\)M for both enzymes\(^\text{25}\); we then conducted the initial *in vitro* kinase assays at that concentration. Under these conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with a half-maximal inhibitory concentration \((IC_{50})\) of 0.2 nM (Fig. 4.3B,C). In view of these results, we named the compound TRULI: “The Rockefeller University Lats inhibitor.” In support of our hypothesis, increases in ATP concentrations yielded positive shifts in the \(IC_{50}\) (Fig. 4.3B).
Chapter 5

The Effects of TRULI in Other Contexts

Because the regenerative effects of activating Yap in organs such as the retina and heart have been characterized extensively\textsuperscript{18,19,41,42}, we investigated whether TRULI treatment is effective in eliciting cellular proliferation in these organs. The results demonstrate that TRULI can faithfully reproduce prior results, otherwise derived with cumbersome techniques, and thus TRULI is likely to be a widely applicable approach for researchers in various fields. Moreover, derivatives of TRULI, which are optimized for \textit{in vivo} application, may offer therapeutic modalities in various pathologies.

Section 5.1: Cardiomyocyte Data

The proliferative capacity of cardiomyocytes in culture and the capacity of the heart to regenerate decline sharply after birth\textsuperscript{41}. To ascertain whether TRULI activates Yap and induces regeneration, collaborators at Weizmann Institute exposed P0 murine cardiomyocytes to TRULI for 3 d. In control cultures, protein blotting revealed high levels of phospho-Yap indicative of Hippo activity. TRULI treatment reduced the proportion of phosphorylated Yap and induced cardiomyocyte proliferation, as demonstrated by a significant increase in the percentage of cells positive for the markers Ki67 and phosphorylated histone H3 (Fig. 5.1A-E). Moreover, treated cells developed cytoskeletal
rearrangements and protrusions and decreased in size, phenotypes consistent with
de-differentiation (Fig. 5.1F,G)\textsuperscript{43}.

**Section 5.2: Retina Organoid Data**

Yap activation can induce retinal regeneration by increasing the proliferation of Müller glial cells, progenitors with a capacity to differentiate into photoreceptors and neurons\textsuperscript{19,20}. To test whether TRULI induces the proliferation of Müller glia, collaborators at Children’s Hospital of L.A. used retinal organoids derived from human induced pluripotent stem cells. Western blotting demonstrated loss of Yap phosphorylation in 24 hr TRULI-treated organoids. And while Müller cells remained largely quiescent in control cultures, in organoids treated for 5 d with 10 µM TRULI, Müller cells exhibited a robust increase in proliferation (Fig. 5.2).
Figure 5.1 TRULI activates Yap in neonatal murine cardiomyocytes, driving proliferation. (A) A protein immunoblot indicates that TRULI decreases the phosphorylation of Yap in neonatal cardiomyocytes in vitro. (B) Quantification of the data in panel A shows the significance of the effect ($p = 0.008$ by an unpaired, two-tailed $t$-test, $n = 4$). (C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the cell-cycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm. (D) Quantification again reveals significant effects for Ki67 ($p = 0.001$ by an unpaired, two-tailed $t$-test, $n = 4$). (E) A marker of mitotic initiation, pH3, is similarly elevated by treatment ($p = 0.026$ by an unpaired, two-tailed $t$-test, $n = 4$). (F) The cardiomyocyte solidity, an index of cellular shape, decreases significantly after treatment, an effect consistent with de-differentiation ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 232$ control cells and 197 TRULI-treated cells). (G) TRULI treatment reduces the areas of cardiomyocytes, another sign of mitosis ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 231$ control cells and 197 TRULI-treated cells).
Figure 5.21 **TRULI activates Yap in human retinal organoids, driving proliferation.**

(A) A protein immunoblot indicates that 24 hr of treatment with TRULI decreases the phosphorylation of Yap in Sox9-marked Müller cells of human retinal organoids. (B) A bar graph documents the effect observed in panel A ($p = 0.024$ by an unpaired, two-tailed $t$-test, $n = 3$). (C) After 5 d of TRULI treatment, EdU labeling shows a substantial increase in cellular proliferation. (D) A bar graph quantifies the result of panel C in three experiments ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 15$ control organoids and 16 TRULI-treated organoids).
**A**

Western blot for pYap, Yap, and Gapdh proteins in Control and TRULI conditions.

**B**

Bar graph showing the pYap/Yap ratio in Control and TRULI conditions. The pYap/Yap ratio is significantly higher in TRULI compared to Control.

**C**

Confocal images showing Sox9 and EdU staining in Control and TRULI conditions. Sox9 staining is more intense in TRULI compared to Control.

**D**

Bar graph showing the percentage of EdU-positive Sox9 nuclei in Control and TRULI conditions. The percentage of EdU-positive Sox9 nuclei is significantly higher in TRULI compared to Control.
In collaboration with the Tri-Institutional Therapeutics Discovery Institute (TDI) we were able to characterize various aspects of TRULI, and the techniques we employed originally became the pipeline with which to screen derivatives generated through medicinal chemistry. In addition to the *in vitro* kinase assay we used in our laboratory, we developed an *in-cell* assay for determining the half-maximal effective concentration of TRULI on Lats-mediated Yap phosphorylation in live cells. When combined with data generated by TDI, both in house and through contract research organizations, these techniques demonstrated that TRULI is a direct, potent, and relatively selective inhibitor of Lats1/2 kinases. After several generations of optimization, lead compounds demonstrated 1000-fold increases in *in vitro* potency and more than 10-fold increase in *in-cell* potency and mouse utricle explant sensitivity. The most potent derivatives also halved the time required for the effect in utricle explants, a promising development for *in vivo* applications. The final suite of derivates varies across systemic stability, potency, selectivity, and more, yielding a diverse arsenal of compounds that may contain components matching the needs of future biological investigations. Because these compounds are protected under a provisional patent, and much of the intellectual work of designing derivatives was done by TDI, the process of compound optimization is
described in abstract terms, with a focus on elements performed or analyzed in our laboratory.

Section 6.1: *In-Cell Potency*

To determine the in-cell potency of TRULI, we evaluated the content of total Yap and phospho-Yap in HEK293A cells serum-starved in the presence of various concentrations and determined the half-maximal effective concentration of the compound to be 510 nM (Fig. 6.1).

Section 6.2: *Data from Tri-Institutional Therapeutics Discovery Institute*

To assess the selectivity of TRULI, collaborators at TDI first compared the sequences of the putative ATP-binding residues of Lats1 and Lats2 with those of other members of the AGC kinase family. To determine which of these potential off-target kinases are bound, we tested TRULI in a broad kinome-binding panel. Of the 314 kinases tested, 34 bound TRULI more strongly than did Lats1 (Table 6.1A). These values likely represent an upper bound on the number of enzymes susceptible to cross-reactivity: although only kinases bound by a small molecule might be relevant, not all such enzymes are functionally inhibited. The selectivity score, or percentage of kinases for which the inhibitor has an half-maximal displacement concentration below 1 µM, was 18.1. This value compares with 86.0 for the broad-spectrum kinase inhibitor staurosporine and with 18.8 for the clinically approved, selective tyrosine kinase inhibitor dasatinib.
Figure 6.1 | **In-cell determination of TRULI potency.** A kinase assay conducted with serum-starved HEK293A cells indicates a half-maximal effective concentration of 510 nM for TRULI. Starvation does not significantly deplete the total amount of Yap. 
Table 6.1 Specificity of TRULI in binding and function. Colors identify different sub-families of the AGC kinase family. (A) Of 314 kinases in a binding panel, the indicated enzymes bound 1 μM TRULI more strongly than did Lats1 or Lats2. The assay did not test for functional inhibition. (B) Half-maximal inhibitory concentrations (IC50s) of TRULI for selected kinases.
### A

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Affinity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLK4</td>
<td>102.191</td>
</tr>
<tr>
<td>PRKCO</td>
<td>99.155</td>
</tr>
<tr>
<td>CDC7</td>
<td>99.093</td>
</tr>
<tr>
<td>DMPK</td>
<td>97.919</td>
</tr>
<tr>
<td>CDC42BPA</td>
<td>97.161</td>
</tr>
<tr>
<td>HIPK3</td>
<td>95.798</td>
</tr>
<tr>
<td>HIPK2</td>
<td>94.205</td>
</tr>
<tr>
<td>PRKACB</td>
<td>92.922</td>
</tr>
<tr>
<td>CLK2</td>
<td>92.819</td>
</tr>
<tr>
<td>GSK3B</td>
<td>92.698</td>
</tr>
<tr>
<td>PRKCH</td>
<td>90.416</td>
</tr>
<tr>
<td>CDK19</td>
<td>90.205</td>
</tr>
<tr>
<td>PKN2</td>
<td>89.660</td>
</tr>
<tr>
<td>CDK8</td>
<td>88.778</td>
</tr>
<tr>
<td>PRKX</td>
<td>88.131</td>
</tr>
<tr>
<td>BMP2K</td>
<td>86.274</td>
</tr>
<tr>
<td>HIPK1</td>
<td>86.064</td>
</tr>
<tr>
<td>DYRK1A</td>
<td>85.826</td>
</tr>
<tr>
<td>PASK</td>
<td>85.771</td>
</tr>
<tr>
<td>ROCK2</td>
<td>84.111</td>
</tr>
<tr>
<td>CDC42BPG</td>
<td>83.657</td>
</tr>
<tr>
<td>PAK4</td>
<td>83.440</td>
</tr>
<tr>
<td>DYRK1B</td>
<td>81.514</td>
</tr>
<tr>
<td>TGFBR2</td>
<td>81.311</td>
</tr>
<tr>
<td>LRRK2</td>
<td>81.277</td>
</tr>
<tr>
<td>ROCK1</td>
<td>79.232</td>
</tr>
<tr>
<td>PRKG2</td>
<td>79.109</td>
</tr>
<tr>
<td>CLK1</td>
<td>78.062</td>
</tr>
<tr>
<td>PRKCD</td>
<td>77.995</td>
</tr>
<tr>
<td>PKN1</td>
<td>77.735</td>
</tr>
<tr>
<td>MAP4K4</td>
<td>77.535</td>
</tr>
<tr>
<td>DAPK3</td>
<td>77.856</td>
</tr>
<tr>
<td>TAO1</td>
<td>76.404</td>
</tr>
<tr>
<td>LATS2</td>
<td>74.882</td>
</tr>
<tr>
<td>MAP3K7</td>
<td>74.047</td>
</tr>
<tr>
<td>LATS1</td>
<td>73.903</td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>Kinase</th>
<th>IC&lt;sub&gt;50&lt;/sub&gt; (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKA</td>
<td>60</td>
</tr>
<tr>
<td>PKCepsilon</td>
<td>14</td>
</tr>
<tr>
<td>ROCK1</td>
<td>88</td>
</tr>
<tr>
<td>NDR1</td>
<td>1000</td>
</tr>
</tbody>
</table>
whether some of the kinases identified in both approaches were in fact functionally inhibited, we measured half-maximal inhibitory concentration values against four kinases that were high on both lists and represented by multiple family members (Table 6.1B)\textsuperscript{46}. Confirming our assumption, the range of inhibitory potency spanned from 14 nM, a relatively strong inhibition, to 1000 nM, effectively no inhibition. Although it will be necessary to explore other potential off-target kinases, particularly in a tissue-specific context, these data demonstrate that TRULI is a potent, direct, and relatively selective inhibitor of Lats1 and Lats2.

To explore the broader characteristics of TRULI, TDI also performed standard metabolic and toxicology analysis, establishing starting points for the next stage of compound optimization.

**Section 6.3: Medicinal Chemistry**

Drawing on an extensive background of expertise, medicinal chemists from TDI used the limited information at hand to optimize compounds. After dozens of compounds had been designed and synthesized, our group performed the \textit{in vitro} kinase assay, always with controls of TRULI, to look for improved potencies. Superior compounds were noted, and TDI gleaned the lessons from the data, informing new generations of derivatives. Particularly good compounds from each generation were repeated in the \textit{in vitro} kinase assay and then assessed in the in-cell assay.

TRULI was optimized across its three moieties (Fig. 6.2): hinge-binding, core, and hydrophobic R-group. Not surprisingly, most modifications to the hinge-binding region
Figure 6.2 Medicinal chemistry approaches. TRULI comprises three regions: a thiazolimine backbone (green), a hydrophobic benzyl group (blue), and a 7-azaindole hinge-binding motif (red).
yielded complete loss of inhibition. Although many modifications within the core and hydrophobic regions were also found to decrease potency, numerous alterations were found that dramatically increased the compounds’ potencies.

In addition to our assessment of derivative potency, TDI performed pharmacokinetic, toxicity, and specificity studies on the best derivatives of each generation to assess for improvements along these other key characteristics.

Section 6.4: Lead Compounds

After 60 compounds had been made over a period of six months, the best were 1000-fold more potent than TRULI in the in vitro kinase assay and up to 50-fold more potent in mouse utricle explants (Fig. 6.3). Of particular interest for in vivo pursuits, the best compounds were not only more potent, but also halved time required for an effect in adult mouse utricle explants, at a 10-fold lower dosage than TRULI is used (Fig 6.4).

The contract research organization-based analyses also rounded out the characterization of this suite, wherein some compounds demonstrate better specificity, some better solubility, some high and some low systemic stabilities (Table. 6.2). Altogether, this suite offers a robust arsenal of tools for a variety of needs of future biological studies into Hippo-Yap, both in vitro and in vivo.
Figure 6.3 | **Increased potency of derivatives.** Concentrations as low as 100 nM of some derivatives sufficed to drive supporting cell proliferation in adult murine utricle explants. Supporting cell nuclear marker Sall2 (green); nuclei of proliferated cells labeled with Edu (white).
Figure 6.4 | **Decreased response latency in derivatives.** *In vitro* treatment of adult utricle explants with 1 µM of one derivative for only three days elicited robust proliferation; by comparison, TRULI requires five days at 10 µM for a comparable response. Two representative images are shown. Nuclei are labeled with DAPI (blue), and nuclei of proliferated cells labeled with Edu (white).
Table 6.2: **Derivatives of TRULI.** Two derivatives are shown compared to TRULI and its qualities, as characterized by both in-house assays and information generated by TDI through contract research organizations. Green indicates optimal ranges, yellow intermediate values, and red poor quality. Half-maximal inhibitory concentrations (IC50), as measured in the *in vitro* kinase assay, are noted in nanomolar. Over 60 derivatives were generated and patented.

<table>
<thead>
<tr>
<th></th>
<th>TRULI</th>
<th>Congener A</th>
<th>Congener B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LATS IC50 (nM)</strong></td>
<td>150</td>
<td>0.1</td>
<td>44</td>
</tr>
<tr>
<td>Solubility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permeability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse Microsomal Clearance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Microsomal Clearance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytotoxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytocrohme p450 inhibition</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Most experiments demonstrating the regenerative effects of Yap activation in mammalian tissues have used transgenesis, viral transfection, or indirect approaches such as activation of G protein-coupled receptors. Although these studies have provided important proof-of-principle results, manipulation of Yap signaling with small molecules offers a more feasible translational approach and simplifies further investigations. In the work described thus far, our group identified and characterized TRULI, a small-molecule inhibitor of the LATS1/2 enzymes. The results supported our original hypothesis that Yap activation in adult murine utricle would drive supporting cell proliferation. Moreover, TRULI reproduces findings from cardiomyocyte and retinal tissues, suggesting the compound and its derivatives are broadly applicable to any investigator interested in exploring Lats inhibition or Yap activation. Although \textit{in vivo} studies with TRULI suggest that its pharmacokinetic properties are insufficient for this application, the dozens of superior derivatives generated significantly increase the likelihood of success in this endeavor. TRULI and its derivates offer powerful tools for molecular investigations of development, stem cell biology, regeneration, and more; it is even plausible that drugs related to this novel thiazolimine class will prove useful in some therapeutic contexts.
Section 7.1: Next Steps in the Inner Ear

TRULI offers a novel avenue into investigating the possibility of mitotic regeneration in the mammalian inner ear. The next steps to achieve this goal include further characterizing and optimizing the transdifferentiation of supporting cells into mature hair cells, exploring the potential for Yap reactivation in the cochlea, and finally demonstrating any and all of these steps *in vivo*.

The initial data on hair cell generation are promising. RNA-sequencing analysis done by Dr. Ksenia Gnedeva showed that TRULI treatment reprograms supporting cells in the utricle to a more plastic state\(^{25}\). After undergoing division, supporting cells re-enter G0 upon drug withdrawal, and many cells shift their nuclei into the hair-cell layer; the pattern is strikingly similar to the regenerative response in non-mammalian vertebrates\(^6\). Although without a second perturbation *in vitro*, we did not observe markers for mature hair cells by immunohistochemistry, daughter cells upregulate hair cell genes to a modest extent. Notch inhibition with gamma-secretases failed to improve the immunohistochemical readout. However, upon Atoh1 transduction, these cells upregulated Pou4F3, an early hair cell marker. Further characterization of the possible new hair cells is needed, including assessing electrophysiological activity, channel patency, hair bundle formation, and other markers of maturity. The experiments conducted heretofore involved explant culture, a fairly toxic environment for hair cells, and therefore the system might simply have been incompatible with the generation of fully mature hair cells. Taken together, our data suggest that combining Hippo inhibition with
a second perturbation driving transdifferentiation might constitute an effective approach to restoring hair cells.

One primary reason for using the utricle as a model organ is that the adult cochlea is difficult to culture in explants and in vivo approaches are technically challenging. Because a neonatal cochlea explant survives for days in culture, we were able to assess the effect of TRULI in this context. After five days of exposure, supporting cells largely remained quiescent, but there were strong proliferative effects in the greater epithelial ridge, a transient developmental tissue thought to harbor precursor cells for the sensory epithelia. Several issues might be at play. One key factor in several regenerative fields is that proliferative responses are minimal without damage. In the adult utricle explant, it is known that over half of the hair cells die in culture within 24 hours, which might enable the proliferation we observe. The hair cells of the neonatal cochlea remain intact, however, which might preclude supporting cell proliferation. Moreover, the epigenetic status of cochlear cells has been shown to be more restrictive, and the chromatin less accessible, than is the case for the utricle. These factors suggest that either damage, more potent derivatives, or longer exposure might tip the scales towards regeneration. If these approaches fail to drive supporting cell proliferation, multiple pathways might need to be targeted. As described in the Introduction, several cyclin kinase inhibitors are active in the cochlea, but not in the utricle, offering other potential targets.

Many of the aforementioned issues stem from the robust, but problematic, explant system. We must ultimately prove the utility of Yap activation in vivo. Although technically more challenging, this approach circumvents many of the issues at hand. The tissue is in
its endogenous context, replete with its natural nutrients, growth factors, and blood supply, in the correct ionic milieu, and more. With techniques that have been developed to induce hair cell loss specifically, and without effecting the other cell types, we can ablate these cells, followed by treatment with TRULI or its superior derivatives. Given the pharmacokinetics of the compounds, the use of slow-release gels injected into the middle ear will likely be a key aspect of our future approach. These experiments will enable us to answer the remaining questions: can daughter cells in the utricle convert into mature, functioning hair cells in the endogenous context, or is a second perturbation required; and can Yap activation drive supporting cell in the mature organ of Corti?

Section 7.2: Other organs

Because TRULI can drive the proliferation of murine cardiomyoctyes and human Müller cells, we believe that the compound could be widely applicable to various lines of investigation into Hippo-Yap signaling. This pathways has been implicated in the development of many tissue types; regeneration in the liver, intestine, lungs, and skin; cancer\textsuperscript{45}; numerous neurodegenerative diseases\textsuperscript{48}; regulation of the mitotic spindle\textsuperscript{49}; cross-talk with important pathways such as Wnt\textsuperscript{50}, p53\textsuperscript{51}, Notch\textsuperscript{52}, and estrogen receptor\textsuperscript{51}; and more. To further demonstrate the breadth of utility, we have initiated several collaborations that have in part validated our expectations.

A potential concern about Lats inhibition is oncogenic transformation. The side effects of Lats inhibition might be mitigated by local application in isolated fluid compartments such as the endolymph of the inner ear, vitreous humor of the retina, and
pericardium of the heart. Moreover, the relationship of Yap to cancer is complex. Yap activation is a marker for poor prognosis in some cancers, but the opposite is true in other instances\textsuperscript{49}. Mutations of proteins in the Hippo pathway are rarely causative of cancer, but are instead secondary to the molecular changes associated with tumorigenesis\textsuperscript{15}. In fact, activation of Yap through deletion of Lats kinases in certain syngenic tumors decreases their progression and metastasis in immune-competent mice by augmenting the immune response\textsuperscript{44}. Given these results, we have established a collaboration with Dr. Elaine Fuchs at Rockefeller University. Together, we will explore whether Yap activation can mimic the effect of Lats deletion in these contexts. We hypothesize that treatment of squamous cell carcinomas with TRULI in mice will slow tumor progression and decrease metastasis.

Among the neurodegenerative disease, the role of Hippo-Yap signaling is the best characterized in the pathophysiology of Huntington’s Disease\textsuperscript{54,55}. One study demonstrated that Yap activation in the nervous system of a mouse model of the disease ameliorates behavioral deficits in vivo\textsuperscript{54}. To test whether TRULI sheds light on the mechanism of Huntington’s Disease, or offer insights into potential therapies, we are collaborating with a team from Dr. Ali Brivanlou’s group at Rockefeller University. Using human induced pluripotent stem cell (iPSCs)-derived neuruloids with mutations in the huntingtin protein, we hope to explore the developmental relevance of deregulated Yap signaling in Huntington’s Disease.

Yap activation has also been shown to augment the process of converting fibroblasts to iPSCs\textsuperscript{56,57}. To explore whether TRULI offers either an investigatory tool or
a tool for improved iPSC generation, we have established a collaboration with Dr. Todd Evans at Weill Cornell Medical College. Together we are assessing whether TRULI can improve the generation of mouse and human iPSC’s, and furthermore we are exploring what aspects of molecular biology within these systems this compound might illuminate.

Within our own group, we have also applied TRULI to the study of regenerating neuromasts in the zebrafish. It is poorly understood how the number of sensory hair cells is so tightly controlled, and the molecular signals underlying the regeneration these cells are only partially understood. We are using TRULI to explore whether Hippo/Yap signaling plays a role in this context; our preliminary results strongly suggest this pathway is highly relevant to the process.

We are also continuing our collaboration with Drs. Aaron Nagiel and Ksenia Gnedeeva, who are attempting to extend our findings in retinal organoids to the retina in vivo. We hope that the use of TRULI’s derivatives offers an approach to retinal regeneration as well.

Together, these endeavors demonstrate that TRULI is a widely applicable and useful tool in numerous potential areas of investigation.
Small-molecule inhibition of Lats kinases promotes Yap-dependent proliferation in postmitotic mammalian tissues

Nathaniel Kastan\textsuperscript{a,1}, Ksenia Gnedeva\textsuperscript{b,1,*}, Theresa Alisch\textsuperscript{a}, Aleksandra A. Petelski\textsuperscript{a,2}, David J. Huggins\textsuperscript{c}, Jeanne Chiaravalli\textsuperscript{d,3}, Alla Aharanov\textsuperscript{e}, Avraham Shakked\textsuperscript{e}, Eldad Tzahor\textsuperscript{e}, Aaron Nagiel\textsuperscript{f}, Neil Segil\textsuperscript{b}, and A. J. Hudspeth\textsuperscript{a}

* Corresponding author: Dr. K. Gnedeva

University of Southern California,
Los Angeles, CA 90033
E-mail: gnedeva@usc.edu

Keywords: cardiomyocyte, hair cell, Hippo pathway, inner ear, Müller glia, supporting cell, Taz, utricle

\textsuperscript{1} These authors contributed equally to the research.

\textsuperscript{2} Current address: Department of Bioengineering and Barnett Institute, Northeastern University, Boston, MA 02115, USA

\textsuperscript{3} Current address: Institut Pasteur, 25-28 Rue du Dr. Roux, Paris 75015, France
\textsuperscript{a} Howard Hughes Medical Institute and Laboratory of Sensory Neuroscience, The Rockefeller University, New York, NY 10065, USA

\textsuperscript{b} Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research and Tina and Rick Caruso Department Otolaryngology-Head and Neck Surgery, University of Southern California, Los Angeles, CA 90033, USA

\textsuperscript{c} Tri-Institutional Therapeutics Discovery Institute, New York, NY 10021, USA; Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA

\textsuperscript{d} High-Throughput Screening Resource Center, The Rockefeller University, New York, NY 10065, USA

\textsuperscript{e} Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel

\textsuperscript{f} Vision Center, Department of Surgery, Children’s Hospital Los Angeles, Los Angeles, CA, USA; Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA, USA; USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Summary

Hippo signaling is an evolutionarily conserved pathway that restricts organ growth during development and suppresses regeneration in mature organs\textsuperscript{1–3}. Using a high-throughput phenotypic screen, we have identified a potent, non-toxic, and reversible inhibitor of Hippo signaling. An ATP-competitive inhibitor of Lats kinases, the compound causes Yap-dependent proliferation of murine supporting cells in the inner ear, murine cardiomyocytes, and human Müller glia in retinal organoids. RNA sequencing indicates that the substance fosters both the G1-S and G2-M checkpoint transitions and yields supporting cells capable of transdifferentiation. Upon withdrawal of the compound, a subset of supporting cells move their nuclei into the hair-cell layer and express genes characteristic of hair cells. Viral transfection of Atoh1 induces the expression of hair cell-specific proteins in progeny. The compound promotes the initial stages of the proliferative regeneration of hair cells, a process thought to be permanently suppressed in the adult mammalian inner ear.

Introduction

Initiated in response to injury, regeneration is a complex process that can restore the structure and function of damaged tissue. Some adult mammalian tissues retain a gradually declining regenerative capability. Regeneration occurs either by activation and amplification of resident stem cells, as in the epithelia of the skin and intestine, or through cellular de-differentiation and proliferation, as in the liver. In other instances, such as central nervous and cardiac-muscle tissues, cells exhibit little or no potential for regeneration after injury\textsuperscript{1,4,5}.

One prominent example of a mammalian organ with poor regenerative capacity is the inner ear\textsuperscript{6,7}. The auditory and vestibular sensory epithelia of all vertebrates possess only two major cell types: supporting cells, which play homeostatic and architectural roles,
and mechanosensitive hair cells. In non-mammalian vertebrates such as birds, lost hair cells are replaced by residual supporting cells that transdifferentiate into new sensory receptors either directly or after undergoing division. Although modest numbers of hair cells regenerate through supporting-cell transdifferentiation in the neonatal mammalian cochlea and in neonatal and adult vestibular organs, after the first postnatal week no proliferative response occurs following damage.

In view of its fundamental roles in development, proliferation, stem-cell maintenance, and de-differentiation, Hippo signaling is an inviting target for driving regeneration. The canonical Hippo pathway is a highly conserved signal-transduction cascade that comprises two pairs of core kinases. When proliferation is unwarranted, Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn phosphorylate the transcriptional co-activator Yap and its homolog Taz, which as a result are sequestered and degraded in the cytoplasm. When the pathway is inactive, Yap enters the nucleus, interacts with transcription factors of the Tead family, and initiates cell division. Yap signaling integrates a variety of information from the cellular environment, including biomechanical cues, cell density, cell polarity, metabolic challenges, and signals such as Notch and Wnt. The Hippo cascade is the conduit through which much, but not all, of this information is integrated into a decision regarding Yap activation.

The regenerative potential of the Hippo pathway has become abundantly clear in numerous organs, including the heart, retina, liver, and intestine. We earlier demonstrated that Hippo signaling limits the size of the developing murine utricle, a vestibular sensory organ, and that the Yap-Tead complex is active during—and necessary for—proliferative regeneration in the neonatal utricle. These observations suggested that chemical activation of Yap signaling might engender supporting-cell proliferation in adult tissue, a key missing step in the regeneration of the mammalian inner ear. We therefore conducted a small-molecule screen for Yap activators.
Results

Identification of activators of Yap signaling

In some monolayer epithelial cultures, increased cell density leads to Hippo activation and thus retention and degradation of Yap protein, a process reminiscent of growth restriction during normal development\textsuperscript{20,21,22}. To seek inhibitors of this process, we designed a high-throughput phenotypic screen for compounds that promote nuclear Yap translocation in confluent human cell cultures (Fig. 1A). After testing three lines, we chose MCF 10A mammary epithelial cells, which demonstrated a robust negative correlation between cellular confluence and the fraction of cells with nuclear Yap (Figs. 1B,C and S1A).

For the small-molecule screen, we seeded MCF 10A cells to achieve dense cultures in 384-well plates. A single compound was deposited in each well at a concentration of 10 µM. Every plate also included a positive control, sub-confluent cells, and a negative control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a concentration equivalent to that in which the compounds were applied. After 24 hr incubation, we determined the fraction of the cells with nuclear Yap and compared that value to the median negative-control value (Fig. 1D). We also scored the total number of surviving cells in each well and eliminated the compounds that decreased the number by more than one standard deviation in comparison to the dense control cultures. Nontoxic compounds that increased nuclear Yap by more than one standard deviation in comparison to the negative control were scored as hits (Fig. S1B,C). Owing to the robustness of contact inhibition in the dense cell cultures, only six of the compounds screened met these criteria.
Yap-dependent proliferation of supporting cells evoked by TRULI

Using utricles isolated from mice eight to twelve weeks of age, we next tested the effects of the six compounds identified in the screen. Four elicited appreciable Yap nuclear translocation, but only two evoked supporting-cell proliferation. Of the two proliferation-inducing compounds, one required a concentration in excess of 100 µM and appeared toxic to hair cells. The final compound, N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, drove robust Yap nuclear translocation after 24 hr of treatment at a concentration of 10 µM and caused a striking reduction in the level of Yap phosphorylation (Figs. 2A,B,D and S2A). After 5 d of treatment, this substance evoked robust re-entry into the cell cycle of adult utricular supporting cells (Fig. 2C,E). For the sake of brevity we term this substance "TRULI."

We also tested the recently published inhibitor of Mst1 and Mst2 kinases, XMU-MP-1. Although XMU-MP-1 reduced the amount of phospho-Yap, it decreased the total Yap by a greater amount so that the ratio actually increased (Fig. S2A,B). No significant proliferation was observed after 5 d of treatment (Fig. S2C).

We additionally assessed the effect of TRULI in the murine cochlea. Although a proliferative response was observed in Kölliker's organ, where progenitor-like cells capable of differentiating into both hair and supporting cells reside, all but the most lateral rows of supporting cells in the organ of Corti remained postmitotic after treatment with TRULI (Fig. S3).

To test whether the proliferative effect of TRULI is exerted through Yap, we co-treated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between Yap or Taz and Tead transcription factors. Consistent with the hypothesis, co-treatment with verteporfin precluded a proliferative response (Fig. 2C,E). To confirm these results, we used SOX2-CreER and Yapfl/fl mice to generate inducible conditional-knockout animals deficient for the protein in the sensory organs of the inner ear. Owing to the stability
of Yap protein\textsuperscript{28}, Cre-mediated recombination was induced either 7 d or 14 d prior to utricular explantation and culture. In the utricles isolated from \textit{Yap\textsuperscript{fl/fl}} littermate mice lacking Cre recombinase, treatment with TRULI elicited robust proliferation of supporting cells (Fig. 2F,G). In contrast, in utricles explanted from Yap knockout animals, proliferation was significantly reduced.

**Blockage of Lats-dependent Yap phosphorylation by TRULI**

We investigated the mechanism of TRULI’s inhibition in the MCF 10A cell line. After treatment of confluent cells with 10 μM of TRULI for 24 hr, protein blotting revealed that the Hippo signaling cascade was intact through the phosphorylation of the activation loops of Lats1 (S909) and Lats2 (S872) (Fig. 3A). However, the phosphorylation of Yap at residue S127 was decreased, suggesting that TRULI is—directly or indirectly—an inhibitor of Lats kinases.

To confirm this inference we turned to HEK293A cells, which activate Lats kinases in response to serum starvation and thus inactivate Yap to prevent growth during nutrient deprivation\textsuperscript{29,30}. We pre-treated 80 % confluent HEK293A cells with 10 μM TRULI for 1 hr, followed by 30 min of serum starvation. In control cultures, starvation elicited robust phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127 (Fig. 3B). In cultures pre-treated with TRULI, however, serum starvation failed to evoke phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed conditions, phospho-Yap levels were below those of serum-fed control cells. Negative-feedback regulation in response to elevated Yap activity might explain why the amount of Lats1 S909 was enhanced in the treated, serum-fed condition\textsuperscript{31}. These results together confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap.
Direct inhibition of Lats1 and Lats2 by TRULI

The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding motifs of ATP-competitive kinase inhibitors (Fig. 3C) Because there are no known crystal structures of the Lats kinases, we created a homology model from the crystal structure of the ATP pocket of similar kinase ROCK1 bound to a small-molecule inhibitor containing a 7-azaindole moiety. A putative structure of the complex between Lats1 and TRULI was then generated by molecular docking (Fig. 3D). Because the predicted protein-ligand contact residues of Lats1 and Lats2 are almost completely conserved, the model suggests that TRULI can bind either with similar inhibitory potencies.

To test our speculations about the mechanism of TRULI inhibition, we optimized an in vitro kinase assay using truncated forms of Lats1 (residues 589-1130) and Lats2 (residues 553-1088) that include primarily the kinase domains (Fig. S4A-C). As a substrate we employed the peptide STK1, which is known to be phosphorylated by these enzymes. Because we hypothesized TRULI was ATP-competitive, we first determined the Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 µM for both enzymes, at which we ran the initial in vitro kinase assays (Fig. S4A). Under these conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with a half-maximal inhibitory concentration (IC$_{50}$) of 0.2 nM (Figs. 3E and S4D), whence the name TRULI: “The Rockefeller University Lats inhibitor." In support of our hypothesis, increases in ATP concentrations yielded positive shifts in the IC$_{50}$ (Fig. 3E).

To determine the potency of TRULI in living cells, we evaluated the content of total Yap and phospho-Yap in HEK293A cells serum-starved in the presence of various concentrations of TRULI. The half-maximal effective concentration of the compound was EC$_{50}$ = 510 nM (Fig. 3F).

To assess the selectivity of TRULI, we first compared the sequences of the putative ATP-binding residues of Lats1 and Lats2 with those of other members of the
AGC kinase family (Tables S1 and S2). To determine which of these potential off-target kinases are bound, we tested TRULI in a broad kinome-binding panel. Of the 314 kinases tested, 34 bound TRULI more strongly than Lats1 (Table S3). These values represent an upper bound: although only kinases bound by a small molecule might be relevant, not all such enzymes are functionally inhibited. The selectivity score, or percentage of kinases for which the inhibitor has a half-maximal concentration of binding displacement below 1 µM, was 18.1. This value compares with control values of 86.0 for the broad-spectrum kinase inhibitor staurosporine and of 18.8 for dasatinib, a clinically approved selective inhibitor of tyrosine kinases. To assess whether some of the kinases identified in both approaches were in fact functionally inhibited, we measured IC₅₀ values against four kinases that were high on both lists and represented by multiple family members. Some were affected significantly more strongly than others (Table S4). Although it will be necessary to explore other potential off-target kinases, particularly in a tissue-specific context, these data demonstrate that TRULI is a potent, direct, and relatively selective inhibitor of Lats1 and Lats2.

**Gene-expression consequences of TRULI treatment**

To characterize the consequences of Lats-kinase inhibition with TRULI, we analyzed the changes in gene expression triggered by the compound after 5 d of treatment. To facilitate the sorting of supporting cells from treated utricles, we utilized Lfng-EGFP mice, whose supporting cells bear a fluorescent tag. Principal-component analysis of RNA-sequencing data revealed that almost 60% of the variance between TRULI-treated and control samples could be explained by the first principal component and that the three samples collected under each condition clustered closely along that axis (Fig. 4A). Over 70% of differentially expressed genes whose expression changed by at least a factor of two were upregulated after treatment (Fig. 4B). Gene ontology analysis demonstrated
that the terms associated with regulation of the cell cycle were the most enriched amongst up-regulated genes (Fig. 4C).

To assess the biological relevance of the changes in gene expression triggered by TRULI, we compared the FPKM values for the differentially expressed genes to those from late embryonic (E17.5) utricular supporting cells. At that stage such cells remain highly plastic and are capable of both proliferation and differentiation into the new sensory receptors\textsuperscript{38,39}. The expression levels for most cell cycle-related genes (gene-ontology term 0007049) that were differentially expressed in postnatal supporting cells after TRULI treatment were highly similar to those in E17.5 supporting cells (Fig. 4D). In particular, the genes specific to the G1-S and G2-M stages of the cell cycle were significantly up-regulated by TRULI to the embryonic levels of expression (Fig. 4E,F). Consistent with the pro-survival role of Yap-Tead signaling, TRULI repressed expression of a subset of inflammatory and pro-apoptotic genes.

The direct targets of the Yap-Tead complex have been identified in other contexts, such as in mammary cancer cells\textsuperscript{40}. In accord with the compound's acting as an activator of nuclear Yap signaling, over 90 % of confirmed direct downstream targets of Yap-Tead complex identified within differentially expressed genes were up-regulated in response to TRULI treatment (Fig. 4G,H). Consistent with our demonstration of a role for Yap in the development of the utricular sensory epithelium\textsuperscript{41}, most of these Yap-target genes were also highly expressed in E17.5 supporting cells.

Inhibition of Lats kinases by TRULI had no apparent toxic effect on utricular supporting cells: genes associated with cell death (gene-ontology term 0008219) remained unchanged after treatment (Fig. 4I).

**Supporting-cell differentiation after TRULI treatment**

To determine whether the increased supporting-cell proliferation triggered by TRULI can be reversed, we performed EdU pulse-chase experiments following TRULI treatment. The
mitogenic effects of Lats inhibition persisted for 24-48 hr after drug withdrawal, for many supporting cells incorporated EdU during that interval (Fig. S5). However, most supporting cells exited the cell cycle thereafter.

Forcing postmitotic cells to re-enter the cell cycle can result in arrest at the G1-S or G2-M checkpoint transition and consequently in programmed cell death. To evaluate the long-term outcome of Lats inhibition on supporting cells, we treated three-week-old Lfng-GFP utricles with TRULI for 5 d followed by 5 d of withdrawal. RNA-sequencing analysis demonstrated that the levels of expression for the cell cycle-related genes and the direct Yap targets that were highly up-regulated upon TRULI treatment were indistinguishable between TRULI-treated and control supporting cells (Fig. S6). In addition, we did not observe enrichment for pro-apoptotic genes after TRULI treatment. Instead, the up-regulated genes were associated with the gene-ontology terms related to hair-cell development and function (Fig. 5A,B). These included the genes for hair cell-specific transcription factors such as Atoh1, Pou4f3, Gfi1, and Lhx3 as well as genes encoding important hair-cell proteins: nonmuscle myosins (Myo15, Myo7A, Myo5A), Ca\(^{2+}\) sensors and buffers (Otof, Calb, S100), and transduction machinery (Tmc1, Tomt).

Because the foregoing results suggested the transdifferentiation of newly formed supporting cells, we sought newly formed hair cells by EdU incorporation. Treatment with TRULI did not affect hair-cell or supporting-cell survival, confirming that the compound is not toxic at the effective concentration (Fig. 5C,D). Although almost none of the cells expressed Pou4f3 or Myo7A, many of the EdU-positive supporting-cell nuclei migrated into the hair-cell layer. This pattern is consistent with the first stages of transdifferentiation.

To test whether supporting cells were capable of giving rise to hair cells after they had proliferated, we treated P21 utricles with TRULI and virally transfected the cultures with Atoh1-RFP upon drug withdrawal. Demonstrating a capacity for transdifferentiation into putative hair-cell precursors, many EdU- and Pou4f3-positive cells were observed after Atoh1 transfection (Fig. S6D).
Effects of TRULI on cardiomyocytes and Müller glia

Because the regenerative effects of activating Yap in organs such as the retina and heart have been characterized extensively\(^5,14,15,17\), we investigated whether TRULI treatment is effective in eliciting cellular proliferation in these contexts.

The proliferative capacity of cardiomyocytes in culture and the capacity of the heart to regenerate decline sharply after birth\(^5\). To ascertain whether TRULI activates Yap and induces regeneration, we exposed P0 murine cardiomyocytes to TRULI for 3 d. In control cultures, protein blotting revealed high levels of phospho-Yap indicative of Hippo activity. TRULI treatment reduced the proportion of phosphorylated Yap and induced cardiomyocyte proliferation, as demonstrated by a significant increase in the percentage of cells positive for the markers Ki67 and phosphorylated histone H3 (Fig. 6A-E). Moreover, treated cells developed cytoskeletal rearrangements and protrusions and decreased in size, phenotypes consistent with de-differentiation and proliferation, respectively (Fig. 6F,G)\(^{43}\).

Yap activation may permit retinal regeneration in mammals by stimulating the proliferation of Müller glial cells, progenitors with a capacity to differentiate into photoreceptors and neurons\(^{17,44}\). To test whether TRULI induces the proliferation of Müller glia, we used retinal organoids derived from human induced pluripotent stem cells. As expected, Müller cells remained largely quiescent in control cultures. In organoids treated for 5 d with 10 µM TRULI, however, Müller cells exhibited a robust increase in proliferation (Fig. 6H-K).

Discussion

Most experiments demonstrating the regenerative effects of Yap activation in mammalian tissues have used transgenesis, viral transfection, or indirect approaches such as activation of G protein-coupled receptors by sphingosine-1-phosphate or epinephrine.
Although these studies have provided proof-of-principle results, manipulation of Yap signaling with small molecules represents a more feasible translational approach. In fact, the only other published inhibitor of the Hippo pathway, XMU-MP-1, activates Yap signaling and facilitates healing of the liver and intestinal epithelium after damage\(^\text{18}\). It is noteworthy, however, that in our hands XMU-MP-1 did not promote supporting-cell proliferation in the utricle. This result suggests that other enzymes function redundantly to Mst kinases in the sensory epithelia. These likely include the Map4K kinases, which activate Lats kinases in other contexts\(^\text{45}\). In fact, our RNA-sequencing data revealed that Map4K2, Map4K3, and Map4K4 are all highly expressed in the adult murine utricle. To our knowledge, no enzymes are broadly redundant to Lats1 and Lats2. Inhibition of Lats kinases with TRULI might therefore provide an effective means of inactivating Hippo signaling in a variety of tissues.

Re-entry into the cell cycle is only one component of regeneration; the daughter cells must also assume their correct cell fates. Our data suggest that, in addition to inducing proliferation, TRULI treatment leaves newly formed supporting cells in a plastic state. After undergoing division, supporting cells re-enter G0 upon drug withdrawal, and many cells shift their nuclei into the hair-cell layer and activate expression of characteristic hair-cell genes; the pattern is strikingly similar to the regenerative response in non-mammalian vertebrates\(^\text{8}\). Because these cells can initiate transdifferentiation upon Atoh1 overexpression, combining Hippo inhibition with inhibition of Notch signaling or Atoh1 gene therapy might constitute an effective approach to restoring hair cells.

In contrast to the robust response in the adult murine utricle, the vast majority of supporting cells in the neonatal cocTiktaalikhlea remained quiescent after 5 d of TRULI treatment. A wave of transcriptional up-regulation of \(Cdkn1B\), the gene encoding P27Kip1, is known to control both the timing and the pattern of cell-cycle exit in the organ of Corti\(^\text{46}\). This process seems absent from the utricle. Activation of Wnt signaling promotes proliferation in the neonatal organ of Corti, but the effect primarily involves
Kölliker's organ and the lateral Hensen's cells\textsuperscript{47,48,49,50}. This pattern resembles that observed after treatment with TRULI. To facilitate cell-cycle re-entry, the organ of Corti might require a more prolonged exposure to proliferative stimuli or treatments that target multiple signaling pathways.

Although pharmacological manipulation of the Hippo pathway might prove useful in dealing with many human diseases, much remains unknown about the potential pitfalls of Lats inhibition. In the context of the Hippo pathway Lats1 and Lats2 are considered redundant, but each paralog also has unique functions such as estrogen-mediated signaling and p53 regulation, respectively. Furthermore, Lats kinases and Yap have ancient and conserved non-Hippo functions in spindle-assembly checkpoints and cytokinesis\textsuperscript{51}. TRULI also offers the ability to investigate these non-Hippo functions of Lats kinases, and it would be prudent to understand the implications of Lats inhibition on these pathways prior to therapeutic endeavors.

Another potential concern about Lats inhibition is oncogenic transformation. In this regard the effect of systemic inhibition of Mst kinases is encouraging\textsuperscript{18}: even after long-term administration, no oncogenic transformation was observed in mice treated with XMU-MP-1. Moreover, the impact of Lats inhibition might be mitigated by local application in isolated fluid compartments such as the endolymph of the inner ear, vitreous humor of the retina, and pericardium of the heart. Finally, the relationship of Yap to cancer is complex. Yap activation is a marker for poor prognosis in some cancers, but the opposite is true in other instances\textsuperscript{52}. Mutations of proteins in the Hippo pathway are rarely causative of cancer, but are instead secondary to the molecular changes associated with tumorigenesis\textsuperscript{3}. In fact, activation of Yap through deletion of Lats kinases in certain syngenic tumors \textit{decreases} their progression and metastasis in immune-competent mice by augmenting the immune response\textsuperscript{53}.

In summary, TRULI is a potent, non-toxic, and reversible inhibitor of Lats kinases, and thus a powerful tool for exploring the role of Hippo signaling in a variety of biological
contexts. As expected on the basis of prior work, Yap activation with TRULI induces the proliferation of murine neonatal cardiomyocytes in primary culture and of human Müller glia in retinal organoids. Moreover, the sensory epithelia of the inner ear now join the list of tissues amenable to Yap-mediated regeneration. In view of the ubiquity of these effects, it is plausible that drugs related to this novel thiazolimine class will prove useful in therapeutic contexts.

**Materials and Methods**

**Animal care and strains**

Experiments were conducted in accordance with the policies of the Institutional Animal Care and Use Committees of The Rockefeller University, the University of Southern California, and the Weizmann Institute of Science.

Swiss Webster mice were obtained from Charles River Laboratories. Sox2-CreER, αMHC-Cre, and ROSA26-tdTomato mice were obtained from the Jackson laboratory. Yapfl/fl (Zhang et al., 2010) were provided by Dr. Martin, Baylor College of Medicine.

Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by intercrossing αMHC-cre mice54, which exhibit highly efficiency recombination in cardiomyocytes, with ROSA26-tdTomato mice55 that require Cre-mediated recombination for expression. Both lines were maintained on a C57BL/6 background.

**Chemical libraries**

A total of 140,238 different compounds from a library at The Rockefeller University High-Throughput and Spectroscopy Resource Center were chosen by a quantitative estimate of drug-likeness score56. The compounds originated in the following commercially available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth Junction, NJ), BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego, CA), Specs
(Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and AMRI (Albany, NY). Compound stocks were stored in 384-well polypropylene plates at a final concentration of 5 mM in DMSO at -30 °C.

**High-throughput screen for small-molecule activators of nuclear Yap**

Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T), and two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested for the screen. Of the three lines, only MCF 10A cells display a reproducible correlation between the number of cells seeded and the number of cells adhered after 24h in culture and thus were selected for the screen.

MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor (Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin (Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution. Cell cultures reached 100 % confluence at an approximate density of 3·10^5 cells per square millimeter.

For the small-molecule screen, chemical-library plates were thawed at room temperature and 0.1 μL of each compound was placed in a well of a 384-well assay plates (Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer Janus with Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture medium to achieve a final concentration of 10 μM for each compound and 0.25 % (vol/vol; 35 mM) dimethyl sulfoxide. Negative (100 % confluent) and positive (25 % confluent) control wells included an identical concentration of the DMSO vehicle.

After 24 hr incubation, the cells were fixed, washed thrice in PBS, and immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). The plates were imaged automatically with a 10X objective lens on the ImageXpress XLS wide-field Micro reader (Molecular Devices, Sunnyvale, CA).
with MetaXpress software (Molecular Devices). Using an empty plate to avoid out-of-focus images, we configured a laser-based autofocus routine for automatic well-bottom detection. We imaged DAPI and Yap conjugated to Alexa Fluor 488 with filter cubes for respectively DAPI (excitation, 350-400 nm; emission 415-480 nm) and FITC (excitation, 460-505 nm; emission, 510-565 nm). The acquisition system was configured to image one site per well. After the fluorescence of DAPI had been used to set the image-based autofocus, the exposure time for each fluorophore was determined with a negative-control well in which the fluorescence signal was set to 75 % of the camera’s maximal intensity.

An image-segmentation application from MetaXpress software was used to automatically analyze the images. The number of cells was estimated by selecting an average size and intensity level above the local background in the DAPI channel.

A built-in translocation module that measured the intensity movement from one compartment to another was configured to determine the nuclear or cytoplasmic status of the Yap. These measurements were acquired first for the positive and negative control wells to determine an arbitrary threshold for the intensity ratio that characterized nuclear translocation versus cytoplasmic retardation of Yap. The same threshold was then applied to each well treated with a small-molecule to identify the substances that increased the number of cells with nuclear Yap without affecting cell survival. Positive controls were not used to normalize data, but to confirm whether the cells were healthy and behaving as expected.

Images were stored in the MDCStore database and analyzed using MetaXpress software (Molecular Devices). Output data were uploaded and analyzed using the CDD Vault from Collaborative Drug Discovery (Burlingame, CA).

The compounds showing over 10 % Yap nuclear translocation and over 5,000 cells per field were selected and the corresponding images were checked to verify the phenotype. To determine half-maximal inhibitory concentrations, the selected compounds were re-tested in concentration-response experiments by serially diluting by half for a total
of ten dilutions to achieve assay concentrations ranging from 20 \( \mu \text{M} \) to 0.03 \( \mu \text{M} \). \( IC_{50} \) values were calculated by CDD software. Six compounds were confirmed in this secondary screen.

**Small-molecule Lats inhibitor**

The compound \( N\)-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and herein termed TRULI, was obtained from Enamine LLC (Z730688380, Monmouth Junction, NJ).

**Dissection and culture of inner-ear sensory epithelia**

Internal ears were dissected from mice euthanized with fluothane and placed into ice-cold Hank’s balanced salt solution (HBSS; Gibco14025-092)

Unless indicated otherwise, explanted cultures of the utricle and cochlea were maintained in an incubator at 37°C in the presence of 5% \( \text{CO}_2 \) and 95% \( \text{O}_2 \). The complete growth medium comprised Dulbecco’s modified Eagle medium with nutrient mixture F-12 (DMEM/F12) supplemented with 33 mM \( \text{d-glucose} \) (Sigma G8644), 19 mM \( \text{NaHCO}_3 \) (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine (Sigma G8540), 5 mM nicotinamide (Sigma N0636), 40 \( \mu \)g/L epidermal growth factor (Sigma E9644), 20 \( \mu \)g/L fibroblast growth factor (Sigma F5392), insulin-transferrin-selenite solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco 15240062).

For proliferation assays, utricles were cultured with 10 \( \mu \)M 5-ethyl-2’-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit, Thermo C10340).

**Culture of epithelial cells**

MCF 10A cells were cultured as described above. HEK293A cells were maintained in DMEM (Gibco 11965-092), 10% fetal bovine serum (Sigma F2442), and antibiotic-
antimycotic solution. All cells were incubated at 37 °C in the presence of 5 % CO₂ and 95 % O₂.

**Culture of primary cardiomyocytes**

Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by intercrossing αMHC Cre mice⁵⁴, which exhibit highly efficient recombination in cardiomyocytes, with ROSA26-tdTomato mice⁵⁵ that require Cre-mediated recombination for expression. Both lines were maintained on a C57BL/6 background.

Neonatal primary cardiac cultures were isolated from P0 pups with a neonatal dissociation kit (Miltenyi Biotec,130-098-373) and homogenizer (gentleMACS). Cardiac cultures were seeded in gelatin-coated wells coated with 0.1 % gelatin (G1393, Sigma) in DMEM/F12 medium supplemented with 1% L-glutamine, 1 % sodium pyruvate, 1 % nonessential amino acids, 1 % penicillin-streptomycin solution, 5 % horse serum, and 10 % fetal bovine serum. After culture in 5 % CO₂ for 24 hr at 37 °C, the medium was replaced for an additional 72 hr with bovine serum-free medium containing 0.1 % (vol/vol) DMSO and, for experimental samples, 20 µM TRULI.

**Culture of human pluripotent stem cells and retinal organoids**

The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical Research, Camden, NJ) was maintained using standard methods. Human retinal organoids were produced from these cells⁵⁸. In three independent proliferation assays, five organoids 225-280 d of age per experimental condition were sampled in culture after incubation for 5 d in 10 µM TRULI and 10 µM EdU. The organoids used in the immunoblot analysis were 160-178 d of age and were incubated for 24 hr in 10 µM TRULI.

**Immunohistochemistry of murine inner-ear sensory epithelia**

Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA; Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 % Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358).
The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A (Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied overnight at 4 °C.

Samples were washed with phosphate-buffered saline solution supplemented with 0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled secondary antisera (Life Technologies) were applied in the same solution for 1 hr at room temperature.

Nuclei were stained with 3 mM DAPI.

**Immunofluorescence assays for cardiomyocytes**

Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature, permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled overnight at 4 °C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope.

**Immunofluorescence imaging of retinal organoids**

Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9 (1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed three times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in the serum solution were added for 1 hr at room temperature followed by two washes with PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa Fluor 555 C10338) was followed by a wash with PBS. After incubation with DAPI (1:10,000 in PBS) for 5 min and the application of mounting solution, sections were imaged by confocal
microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA objective lens with a pinhole size set at the first Airy disc.

**Protein immunoblotting and quantification**

MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice between sonications. After lysates had been scraped and centrifuged at 10,000 RPM for 10 min at 4 °C, the supernatants were immediately subjected to electrophoresis or stored at -80 °C.

A standard immunoblotting protocol was used with the following specifications. A 4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156) and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies had been reconstituted in the same solution, the membrane was incubated overnight at 4 °C. After three 5 min washes at room temperature in tris-buffered saline solution with 0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase (Millipore) was applied in the same solution for 1 hr at room temperature before activity was detected (SuperSignal West Pico PLUS, Thermo 34580). Images were acquired with an iBrightFL1000 system.

We used at a dilution of 1:1000 primary antibodies directed against Yap (sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565), phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730), phospho-Mob1 T35 (CST 8699), tubulin (Sigma T6793), and GAPDH (Abcam ab8245).

Cultured cardiomyocytes were lysed using RIPA supplemented with protease and phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of each sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and subsequently transferred to a PVDF membrane. Following 1 hr blocking at room temperature, membranes were incubated with the following antibodies against
phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358, Novus) and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room temperature. Following two washes in tris-buffered saline solution containing 0.1 % Tween 20, membranes were incubated with horseradish peroxidase anti-rabbit or secondary antibodies (Jackson). The signal was detected by super-signal west pico plus chemiluminescence kit (34580, Thermo-Fisher).

Immunoblots were quantified through measurement of band intensity with Fiji\textsuperscript{59}. The final value of each band’s intensity was normalized by the sum of all the bands’ intensities. Significances from Student’s $t$-tests are denoted as follows: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$. Unless otherwise indicated, error bars denote standard errors of means (SEMs).

**Imaging of Yap nuclearization and quantification of proliferation**

Confocal imaging was conducted with a confocal microscope enhanced with structured illumination (VT-iSIM, VisiTech International Ltd.).

For quantification of Yap nuclearization, for each condition two fields of supporting cells were imaged at 60X from two utricles. Using CellProlifer\textsuperscript{60}, we masked Sall2-positive nuclei and measured the intensity of their labeling. The same mask was then applied to the Yap channel and the intensity of labeling was measured. The ratio of the Yap to the Sall2 intensity was calculated for each condition in 680 cells after TRULI treatment and 570 cells for DMSO controls.

For quantifying the proliferation of supporting cells, we imaged utricles at 60X, then assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The maximal values in z-stacks were projected to display the entire supporting-cell layer of the sensory epithelium, excluding connective tissue and the surrounding epithelium. Using CellProlifer\textsuperscript{60}, we counted the number of EdU-positive nuclei. Alternatively, EdU- and Sox2- doubly positive nuclei were counted using Multi-point Tool in ImageJ.

Images acquired from neonatal cardiac cultures were analyzed using ImageJ software by thresholding for cardiomyocytes according to endogenous tdTomato fluorescence. Thresholded figures were carefully and manually separated by fine lines to
de-cluster cells in case they touch, basing on original images, following by measurements of area and solidity.

Images acquired from retina organoids were analyzed with CellProfiler\textsuperscript{60}. Masks were created for all the Sox9-positive nuclei, and the percentage of EdU- and Sox9-positive nuclei were counted.

**In vitro kinase assay**

The *in vitro* kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized to the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2 (Carna 01-124). Reactions were conducted with 10 $\mu$M STK1 substrate and 10 $\mu$M ATP, unless otherwise indicated. For the ATP-shift assay, ATP was also used at concentrations of 50 $\mu$M and 250 $\mu$M. Lats1 was employed at a concentration of 200 pg/µL and Lats2 at 50 pg/µL, unless otherwise indicated. For the assay in which Michaelis-Menten constants for ATP were determined, each enzyme was at a concentration of 62.5 pg/uL, and Lats1 ran for 30 min, and the Lats2 ran for 20 min, all at room temperature. The DMSO concentration was maintained at 0.5 % (vol/vol) throughout all experiments, and a Janus 384 MDT (PerkinElmer) equipped with a 50 nL Pintool (V&P Scientific, Inc.) was used to add the compounds dissolved in DMSO to the reaction. The enzyme, substrate, ATP, and TRULI were combined in a low-volume 384-well plate and shaken for 50 min at room temperature, unless otherwise indicated. The reaction was stopped by adding the detection reagents, which were prepared at an 8:1 biotin:streptavidin ratio, and shaken for 60 min at room temperature. All reactions were conducted in triplicate and a Synergy NEO (Biotek) was used to detect the signal.

**Cellular kinase assay**

HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 cells per well in the medium described above. To start the assay, new serum-free medium with
various concentrations of the compound was added to the cells, which were then incubated for 30 min at 37 °C. The DMSO concentration was kept at 0.1 % (vol/vol), and all experiments were performed in triplicate.

Total Yap and phospho-Yap were detected according to the two-plate protocol for adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127] Cellular Kit, Cisbio 64YapPEG). The signal was detected by Synergy NEO (Biotek).

**Modeling of enzyme structure**

Lats1 and Lats2 are in the AGC kinase family, which also contains kinase sub-families such as Ndr and Rock. In *Homo sapiens*, Lats1 has an overall sequence identity of 51.7% with Lats2, of 42.2% with Ndr2, and of 39.9% with Rock1. Owing to the presence of the classic kinase hinge-binding azaindole motif in TRUL1, we focused on the kinase domain and analyzed the ATP-binding site in order to generate a homology model. To define this site we used the 36 kinase-domain residues defined by Huang et al.61. We show an alignment of these ATP-binding site residues for 62 human AGC kinases (Table S1) and the identities of these residues between Lats and the other AGC kinases (Table S2). It is worth noting that the sequence identity between Lats1 and Lats2 in the ATP-binding site is 97.2%, with only a single conservative difference (lysine to arginine).

To generate a homology model of the kinase domain we selected a complex of Rock1 bound to an azaindole thiazole inhibitor (PDB ID: 5KKS)62. This complex was selected because the sequence identity between Lats1 and Rock1 in the ATP binding site is 72.2% and the bound inhibitor shares an azaindole group with TRUL1. Although the resolution of the structure is a modest 0.33 nm (3.3 Å), the electron density within the ATP-binding site is good and allows the conformation of the ligand and the amino acid side-chains to be determined unambiguously. The protein structure was downloaded from the Protein Databank, selenomethionines were changed to methionines, and missing sidechains were added with Schrodinger’s Preparation Wizard. This program was also used to fix the orientations of the asparagine, glutamine, and histidine residues as well as the protonation states of all ionizable residues. Heteroatomic species such as water...
molecules, buffer solvents, and ions were removed and the complex was energy minimized with a restraint of the all-atom root-mean-square distance to 0.03 nm (0.3 Å). The homology model was generated from residues 705-1043 of Lats1 with a knowledge-based model in Schrodinger’s Advanced Homology tool. Chain B of ROCK1 was used as the template and the azaindole thiazole inhibitor was retained.

The resulting homology model was then used for molecular docking with Schrodinger’s Glide SP. The Glide grid was generated around the azaindole thiazole inhibitor in the ATP-binding site with T845 as a rotatable group. TRULI was prepared using Schrodinger’s Ligprep and docked using Schrodinger’s Glide SP using default input parameters. The Glide SP docking score was -39 kJ/mol (-9.4 kcal/mol), corresponding to a binding affinity of approximately 130 nM.

The ligand’s azaindole group is predicted to bind to the hinge region as expected, whereas the ligand’s thiazolimine group contacts D846 in the DFG loop and the ligand’s benzyl group contacts the C-terminal F1039, which forms the active-site tether in many AGC kinases.

Although the numbers assigned to the amino-acid residues of various proteins elsewhere in the text refer to the murine products, those in the present paragraph reference the human proteins.

**RNA sequencing and data analysis**

Supporting cells were isolated by fluorescence-activated cell sorting from the utricles of Lfng-EGFP mice as described previously. The total RNA was extracted using Quick-RNA MicroPrep kit (Zymo Research) and stored up to 2 weeks at -80 °C. RNA samples were then processed for library preparation with QIAseq FX Single Cell RNA Library Kit (Qiagen) and the quality of the library was confirmed using a Bioanalyzer (Quick Biology Inc.). A minimum of two biological replicates were collected for each condition, and at least 20 million 150 base-paired-end reads were sequenced for each replicate. Reads were mapped to GRCm38/mm10 genome assembly using STAR. Differentially expressed genes were identified by DESeq2. Only the protein coding sequences were considered for FPKM calculation. For data visualization, the ggplot2 package was used.
Principal components analysis was performed with pcaExplorer\textsuperscript{68} on the 1000 genes whose differential expression was most significant.

\textbf{Adenoviral gene transfer}

The AdEasy Adenoviral Vector System (Agilent) was used to create adenoviral vectors containing the full-length coding sequence of murine Atoh1 under the control of a cytomegalovirus promoter. To permit the identification of infected cells, we also included sequences for an internal ribosome-entry site and for RFP. Viral particles were amplified and purified by CsCl-gradient centrifugation followed by dialysis (Viral Vector Core Facility, Sanford Burnham Prebys Medical Discovery Institute). Utricles were infected in 200 μL of culture medium with 10 μL of virus at a titer of $10^{10}$ pfu/mL. Ad-RFP virus (Vector Biolabs) at the same titer were used as a control.

\textbf{Supplemental Information}

Supplemental information can be found in the attached file.

\textbf{Acknowledgments}

This project was made possible by the dedicated personnel of two service facilities. At Rockefeller University's High-Throughput Screening Resource Center directed by Fraser Glickman, Carolina Adura Alcaino helped design assays for enzyme activity. The effort was supported in part by the Robertson Therapeutic Development Fund. At the Tri-Institutional Therapeutics Discovery Institute supervised by Peter Meinke, Leigh Baxt, Stacia Kargman, Robert Myers, and Nigel Liverton assisted with assay design and Rui Liang performed chemical syntheses. Masha Vologodskaiia, Welly Makmura, Juan Llamas, Angela Ferrario, Rosanna Calderon, and Kayla Stepanian provided technical assistance. The pipeline for RNA sequencing data quality control and alignment was modified from EndCode by Litao Tao, Talon Trecek, and Francis James. We thank the
members of our research groups for comments on the manuscript. NK was supported by the NIGMS (T32GM007739); KG by the NIDCD (R21DC016984); TA by the Studienstiftung des deutschen Volkes; AA, AS, and ET by European Research Council (ERC AdG 788194, CardHeal), the Israel Science Foundation (ISF), and the Foundations Leducq and Minerva; AN by Research to Prevent Blindness and the Las Madrinas Endowment in Experimental Therapeutics for Ophthalmology; and NS by the Hearing Restoration Program of the Hearing Health Foundation and the NIDCD (R01DC015829 and R01DC015530). AJH is an Investigator of Howard Hughes Medical Institute.

**Author Contributions**

Conceptualization, KG, AJH, and NK; Methodology, JC, DJH; Formal Analysis, KG and NK; Investigation: KG, NK, TA, AAP, JC, AA, and AS; Resources, ET, AN, NS, and AJH; Writing – Original Draft, NK; Writing – Review and Editing, AJH, KG, NK, NS; Visualization, KG, NK, DJH, and AJH; Supervision, AJH; Funding Acquisition, ET, AN, NS, and AJH

**Declaration of Interests**

KG, NK, TA, AAP, and AJH are parties to an application for patent protection of derivatives of the Lats inhibitor presented here.

**References**


35. http://www.reactionbiology.com/webapps/site/kinaseassay.aspx?gclid=EAIaIQobChMI9K2248-V5wlVyp6zCh2HSwAKEAAYASABEGC65PD_BwE.


**Figures and Figure Legends**
Figure 1. High-throughput screen for activators of Yap translocation to nuclei

(A) A schematic diagram demonstrates the strategy for identification of compounds that promote the nuclear transit of Yap, thus reversing the exclusion characteristic of contact inhibition. (B) The number of MCF 10A cells rises almost linearly with their confluency. (C) Nuclear localization of Yap falls systematically with increasing confluency in MCF 10A cultures. (D) Immunolabeling of Yap (red) demonstrates nuclear localization of the protein in a positive-control (subconfluent) culture and in a negative-control (confluent) culture. Treatment of a confluent culture with a representative hit compound promotes extensive movement of Yap into nuclei.

See also Figure S1.
Figure 2. Activation of Yap and proliferation of supporting cells

(A) A timeline depicts the pattern of the experiments shown in the indicated subsequent panels. Treatment with TRULI is initiated at the outset. (B) TRULI exposure drives Yap into the nuclei of utricular supporting cells. (C) In vitro exposure to TRULI for 5 d elicits proliferation of supporting cells, as measured by the incorporation of EdU. Verteporfin, an inhibitor of the Yap-Tead interaction, drastically reduces this effect. (D) The nuclear localization of Yap is quantified as a ratio to the constitutively expressed protein Sall2 ($p < 0.0001$ by an unpaired, two-tailed t-test, $n = 570$ control nuclei and 680 treated nuclei). (E) The number of EdU-positive cells per utricle increases with TRULI ($p = 0.021$ by an unpaired, one-tailed t-test, control $n = 2$, TRULI $n = 3$), but the effect is blocked by verteporfin ($p = 0.028$ by an unpaired, one-tailed t-test, $n = 2$). (F) Conditional deletion of Yap by tamoxifen administration to SOX2-Cre$^{ER}$ Yap$^{fl/fl}$ (Yap CKO) animals at P1, 7 d or 14 d prior to explantation, decreases the number of Sox2 (red) and EdU (white) doubly
positive supporting cells compared to Cre-negative $Yap^{fl/fl}$ (WT) littermates. (G) Quantification of the number of EdU-positive cells in panel F demonstrates that decrease in supporting-cell proliferation is statistically significant (Student’s t-tests; $n = 3$ for wild-type control and Yap CKO at 7 d; $n = 4$ for TRULI treatment; $n = 6$ for Yap CKO at 10 d and TRULI).

See also Figure S2.
Figure 3. ATP-competitive inhibition of Lats kinases.

(A) Protein immunoblotting discloses that treatment of MCF 10A cells with TRUL1 leaves Hippo signaling intact through the activation of Lats kinases, but that Yap phosphorylation is greatly diminished. (B) Serum starvation of HEK293A cells in the presence of TRUL1 also demonstrates Lats activation but suppression of Yap phosphorylation. (C) TRUL1 comprises a thiazolimine backbone with two substituents: a benzyl group and a 7-azaindole hinge-binding motif. (D) In a simulated structure of TRUL1 in the predicted ATP-binding site of Lats1, the protein is displayed as a ribbon with heavy atoms in atom-colored wire representation with grey carbons. TRUL1 is displayed in an atom-colored, ball-and-stick representation. Aspartate 846 is positioned to bind the thiazolimine group and phenylalanine 1039 to interact with the benzyl moiety. (E) An in vitro assay of Lats1
kinase activity shows that the $IC_{50}$ for TRULI increases with the ATP concentration, from 0.2 nM at 10 μM, to 4.3 nM at 50 μM, and to 80 nM at 250 μM, demonstrating that the compound is an ATP-competitive inhibitor. (F) A kinase assay conducted with serum-starved HEK293A cells indicates an $EC_{50}$ of 510 nM for TRULI. Starvation does not significantly deplete the total amount of Yap. In panels E and F, error bars represent SEs. See also Figures S3 and S4.
Figure 4. Gene-expression changes evoked treatment in supporting cells by TRULI.

(A) For three experiments, principal-component analysis was performed on RNA-sequencing data obtained from supporting cells after 5 d of treatment with TRULI or from control samples. (B) A volcano plot visualizes the differentially expressed genes (| log₂(fold change) | > 1; padj<0.05). Genes upregulated after TRULI treatment compared to control are labeled in red and those downregulated in blue. (C) Gene-ontology (GO) analysis performed with DAVID software demonstrates that the terms associated with the cell cycle are the most enriched in the genes upregulated by TRULI, whereas the terms associated with stress are more enriched in the control gene set. A full list of differentially expressed genes identified using DEseq2 is available on request. (D) For three
experiments, a heatmap demonstrates the relative expression levels of 140 cell-cycle genes differentially expressed between control and TRULI-treated supporting cells (false discovery rate < 0.01) in comparison to E17.5. Highly expressed genes are shown in red and genes with relatively low levels of expression are depicted in blue. (E) Cell-cycle genes of the G1-S transition of the cell cycle are significantly upregulated by TRULI to the levels found in E17.5 supporting cells ($p < 0.001$ by a Wilcoxon signed-rank test). (F) Markers of the G2-M transition are likewise upregulated ($p < 0.001$ by a Wilcoxon signed-rank test). (G) For three experiments, the heatmap demonstrates the relative expression levels of 79 Yap-target genes differentially expressed between control and TRULI-treated supporting cells (false discovery rate < 0.01) in comparison to E17.5 embryonic levels. (H) The expression of Yap-target genes is upregulated in response to TRULI to the levels found in E17.5 supporting cells ($p < 0.05$ by a Wilcoxon signed-rank test). (I) In contrast, the relative level of expression for genes associated with cell death remains unchanged between controls, TRULI-treated, and E17.5 supporting cells ($p > 0.05$ by a Wilcoxon signed-rank test).

See also Figure S5.
Figure 5. Supporting-cell plasticity after TRULI treatment.

(A) A volcano plot visualizes the genes differentially expressed after 5 d of TRULI treatment followed by 5 d drug withdrawal ($|\log_2(fold\ change)| > 1; \text{padj} < 0.05$). The subset of hair-cell genes most upregulated after TRULI treatment compared to control are labeled. (B) Gene-ontology analysis performed with DAVID software demonstrates that the terms associated with hair-cell differentiation and function are the most enriched in the genes upregulated by TRULI. A full list of differentially expressed genes identified using DEseq2 is available on request. (C) In the representative examples of whole mount utricular explants after 5 d of TRULI treatment followed by 5 d drug withdrawal, immunolabeling for Pou4f3 (green) and Myo7a (red) depicts hair cells. New sensory receptors formed from proliferated supporting cells are identified by EdU-incorporation (white) and are found only after TRULI treatment. Nuclei are labeled with DAPI. (D) The total number of hair cells per utricle does not change after TRULI treatment ($p > 0.05$ by a Student’s $t$-test; $n = 4$ for controls and $n = 5$ for TRULI treated animals).
Figure 6. Proliferation of cardiomyocytes and Müller cells.

(A) A protein immunoblot indicates that TRULI decreases the phosphorylation of Yap in neonatal cardiomyocytes *in vitro*. (B) Quantification of the data in panel A shows the significance of the effect (*p* = 0.008 by an unpaired, two-tailed t-test, *n* = 4).

(C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the cell-cycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm. (D) Quantification
again reveals significant effects for Ki67 ($p = 0.001$ by an unpaired, two-tailed $t$-test, $n = 4$). (E) A marker of mitotic initiation, pH3, is similarly elevated by treatment ($p = 0.026$ by an unpaired, two-tailed $t$-test, $n = 4$). (F) The cardiomyocyte solidity, an index of cellular shape, decreases significantly after treatment, an effect consistent with de-differentiation ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 232$ control cells and 197 TRULI-treated cells). (G) TRULI treatment reduces the areas of cardiomyocytes, another sign of mitosis ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 231$ control cells and 197 TRULI-treated cells). (H) A protein immunoblot indicates that 24 hr of treatment with TRULI decreases the phosphorylation of Yap in Sox9-marked Müller cells of human retinal organoids. (I) A bar graph documents the effect observed in panel H ($p = 0.024$ by an unpaired, two-tailed $t$-test, $n = 3$). (J) After 5 d of TRULI treatment, EdU labeling shows a substantial increase in cellular proliferation. (K) A bar graph quantifies the result of panel J in three experiments ($p < 0.0001$ by an unpaired, two-tailed $t$-test, $n = 15$ control organoids and 16 TRULI-treated organoids).
Figure S1. Screening for activators of Yap translocation into nuclei. Related to Figure 1. (A) The adherent properties of three human epithelial-cell lines—one embryonic kidney line (HEK 293T) and two mammary-gland lines (MDA-MB and MCF 10A)—were tested. Only MCF 10A cells display a reproducible correlation between the number of cells seeded and the number of cells adhered after 24 hr. (B) In a representative example of cell survival in ten 384-well plates screened in the assay for nuclear translocation of Yap, the plate indexes are indicated on the x-axis and the total number of cells detected in each well of each plate is indicated on the y-axis. Purple lines demonstrate the average mean (M) and one standard deviation (SD) below the mean of the number of cells detected in each negative control well (blue dots) of each of the ten plates screened. Red dots represent sub-confluent positive control wells; black dots represent each well treated with a compound. The substances that decreased the number of cells over one SD were eliminated owing to toxicity. (C) In the same ten 384-well plates analyzed in panel B, the percentage of cells with nuclear Yap was determined using MetaXpress software. Only one in a thousand compounds increased this value more than one standard deviation (SD; purple line) above the mean value determined for the negative controls (M; purple line).
Figure S2. Lack of Yap activation by the Mst inhibitor XMU-MP-1. Related to Figure 2.

(A) Six utricles per condition were treated for 24 hr with 10 µM TRULI or XMU-MP-1 to assess effects on the amount of phospho-Yap by comparison to control conditions. (B) Quantification of band-intensity ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that XMU-MP-1 does not reduce the fraction of phosphorylated Yap. (C) When adult mouse utricles were explanted and cultured with EdU (white) and either TRULI or varying concentrations of XMU-MP-1, the latter caused no increase in proliferation. Nuclei are stained with DAPI (blue).
Figure S3. Proliferative response in the cochlea after treatment with TRULI. Related to Figure 2. (A) No hair-cell loss is observed after 5 d of treatment of the P1 organ with 10 \( \mu \)M TRULI. Only the most lateral rows of Hensen’s cells re-enter the cell cycle after the treatment. (B) TRULI elicits robust proliferation of Sox2-positive cells in Kölliker’s organ, as measured by the incorporation of EdU.
Figure S4. Optimization and further results of in vitro kinase assay. Related to Figure 3.
(A) In order to perform assays at an appropriate ATP concentration, we established the Michaelis-Menten constants for Lats1 ($K_m = 9.4 \mu M$) and Lats2 ($K_m = 7.6 \mu M$). (B) A kinetic assay for Lats1 was used to determine the optimal signal-to-noise ratio within the linear range of product formation. Enzyme concentrations are indicated in micrograms per liter. (C) The corresponding assay was performed for Lats2. (D) The half-maximal inhibitory concentration of TRUL1 against Lats2 was $IC_{50} = 0.2 \text{nM}$. 
Figure S5. Cell-cycle exit after TRULI withdrawal. Related to Figure 4. (A) As shown in the timelines to the left, utricles were explanted and cultured for 5 d in the presence of TRULI; EdU was then added at various times. In first top row, when EdU was present throughout the 5 d period of culture, extensive proliferation occurred in the striolar region. The second row shows that proliferation was still heavier when EdU was presented during the day following TRULI exposure. The third row indicates that proliferation declined during the second day after TRULI withdrawal. The fourth row demonstrates that proliferation fell to nearly the background level when EdU was provided three days after the withdrawal of TRULI. (B) A bar graph quantifies the number of EdU-positive nuclei per sensory epithelium in the foregoing experiments. Each datum is an average from two utricles.
Figure S6. Cell-cycle exit and hair cell differentiation after TRULI withdrawal. Related to Figure 5. (A) RNA-sequencing analysis demonstrates that the genes active in G2-M are downregulated to the control levels in P21 supporting cells 5 d after TRULI withdrawal. (B) S-phase genes are similarly downregulated. (C) Genes known to be targets of the Yap-Tead complex are also downregulated. (D) To assess whether new hair cells can be formed after TRULI treatment, P21 utricles that had been treated with TRULI for 5 d were cultured for two days to allow cell-cycle exit, then transfected with adenovirus carrying Atoh1. The cultures were co-treated with EdU to permit lineage tracing of supporting cells that had undergone cell division in the presence of TRULI. After 5 d of Atoh1 expression, many EdU-positive supporting cells displayed high levels of Pou4f3 protein, demonstrating the potential of supporting cells to transdifferentiate.
Table S1. Alignment of residues at the ATP-binding sites of AGC kinases. Related to Figure 3. These 36 residues define the ATP-binding pockets of 62 kinases, but do not represent continuous sequences.

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Residues</th>
</tr>
</thead>
<tbody>
<tr>
<td>LATS1</td>
<td>LGIGAFGEVAKRLFVMDYIPGDMNSDKDLNLDFG</td>
</tr>
<tr>
<td>LATS2</td>
<td>LGIGAFGEVAKVLVFVMDYIPGDMNSDKDLNLDFG</td>
</tr>
<tr>
<td>NDR1</td>
<td>IGRGAFGEVAKLMFIMELPGDMMTDKDLNSDFG</td>
</tr>
<tr>
<td>NDR2</td>
<td>IGRGAFGEVAKLMFIMELPGDMMTDKDLNSDFG</td>
</tr>
<tr>
<td>ROCK1</td>
<td>IGRGAFGEVAKQLMVMYHPGDLVNDKDLNADF</td>
</tr>
<tr>
<td>ROCK2</td>
<td>IGRGAFGEVAKQLMVMYHPGDLVNDKDLNADF</td>
</tr>
<tr>
<td>RSKL2</td>
<td>VQDPATGGTMSGPGLNLTPARLPSDGNLTYNFG</td>
</tr>
<tr>
<td>SgK494</td>
<td>VAKGSFGTVAKHSLMSCSTDLYSLDKEMLTDFG</td>
</tr>
<tr>
<td>PDK1</td>
<td>LGEGSFSTVAKVLFLGSLYAKNGELLKDLNKEMLTDFG</td>
</tr>
<tr>
<td>RSK4</td>
<td>LGQSFGKVKVLLILDFLRGDVFDTKDLNADF</td>
</tr>
<tr>
<td>RSK1</td>
<td>LGQSFGKVKVLLILDFLRGDVFDTKDLNADF</td>
</tr>
<tr>
<td>RSK3</td>
<td>LGQSFGKVKVLLILDFLRGDVFDTKDLNADF</td>
</tr>
<tr>
<td>RSK2</td>
<td>LGQSFGKVKVLLILDFLRGDVFDTKDLNADF</td>
</tr>
<tr>
<td>p70S6K</td>
<td>LGKGGYGKVKAVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>p70S6Kb</td>
<td>LGKGGFGKVKAVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>MSK1</td>
<td>LQGTAIGKVKVLILFYSGEMFTKDLNADF</td>
</tr>
<tr>
<td>MSK2</td>
<td>LQGTAIGKVKVLILFYSGEMFTKDLNADF</td>
</tr>
<tr>
<td>YANK2</td>
<td>IGKGSFGKVKAVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>YANK3</td>
<td>IGKGSFGKVKAVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>YANK1</td>
<td>IGKGSFGKVKAVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>PKCi</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>PKCz</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>SGK</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>SGK2</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>SGK3</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>RKN3</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>RKN2</td>
<td>LQGSHFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>AKT1</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>AKT2</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>AKT3</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCt</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCd</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCe</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCh</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCg</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>PKCa</td>
<td>LGKTFGVVKATLFLVEMAYNGGELFFDKENMTDFG</td>
</tr>
<tr>
<td>BARK2</td>
<td>IGRGGEVAKCMILILNDGDLHYKSLNLGD</td>
</tr>
<tr>
<td>BARK1</td>
<td>IGRGGEVAKCMILILNDGDLHYKSLNLGD</td>
</tr>
<tr>
<td>GPRK5</td>
<td>LGKGGFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>GPRK6</td>
<td>LGKGGFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>GPRK5</td>
<td>LGKGGFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>GPRK4</td>
<td>LGKGGFGKVKVLLILFSLGELFMDKDLNADF</td>
</tr>
<tr>
<td>MAST3</td>
<td>ISNGAYGAVKSMQVEYGEGDDCATDKDLNADF</td>
</tr>
<tr>
<td>MAST4</td>
<td>ISNGAYGAVKSMQVEYGEGDDCATDKDLNADF</td>
</tr>
<tr>
<td>MAST2</td>
<td>ISNGAYGAVKSMQVEYGEGDDCATDKDLNADF</td>
</tr>
<tr>
<td>MAST1</td>
<td>ISNGAYGAVKSMQVEYGEGDDCATDKDLNADF</td>
</tr>
<tr>
<td>CR1K</td>
<td>VQGCHFAEVAKQPQLVMEYQPGDGLSSDKNVLDFG</td>
</tr>
<tr>
<td>MASTL</td>
<td>ISNGAYGAVKSMQVEYGEGDDCATDKDLNADF</td>
</tr>
<tr>
<td>DMPK1</td>
<td>IGRGAFSEVAKQLVEYVQGDLDDTDLNLNADF</td>
</tr>
<tr>
<td>MRCb</td>
<td>IGRGAFSEVAKQLVEYVQGDLDDTDLNLNADF</td>
</tr>
<tr>
<td>DMPK2</td>
<td>IGRGAFSEVAKQLVEYVQGDLDDTDLNLNADF</td>
</tr>
<tr>
<td>MRCb</td>
<td>IGRGAFSEVAKQLVEYVQGDLDDTDLNLNADF</td>
</tr>
<tr>
<td>PKG2</td>
<td>LGVGFGFRVAKKLMELLEACGLGDLHSKDNVLDFG</td>
</tr>
<tr>
<td>PCK1</td>
<td>LGVGFGFRVAKKLMELLEACGLGDLHSKDNVLDFG</td>
</tr>
<tr>
<td>PKX</td>
<td>VQGTGTFGRVAKTMLRELVEYVFEGGFLSDKENLTFDG</td>
</tr>
<tr>
<td>PKY</td>
<td>MGTGTFGRVAKTMLRELVEYVFEGGFLSDKENLTFDG</td>
</tr>
<tr>
<td>PKAcg</td>
<td>LGMGSFGRVAKLMLKVMEYPGEMFSDKENLTFDG</td>
</tr>
<tr>
<td>PKAcb</td>
<td>LGMGSFGRVAKLMLKVMEYPGEMFSDKENLTFDG</td>
</tr>
<tr>
<td>PKCa</td>
<td>LGMGSFGRVAKLMLKVMEYPGEMFSDKENLTFDG</td>
</tr>
</tbody>
</table>

122
Table S2. Percentage sequence identity for the 36 residues of the ATP-binding site between Lats1 and Lats2 and AGC kinases. Related to Figure 3. In this and the subsequent two tables, colors identify different sub-families of the AGC kinase family.

<table>
<thead>
<tr>
<th>AGC kinase</th>
<th>Identity to Lats1 (%)</th>
<th>Identity to Lats2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LATS1</td>
<td>100.0</td>
<td>97.2</td>
</tr>
<tr>
<td>LATS2</td>
<td>97.2</td>
<td>100.0</td>
</tr>
<tr>
<td>PKACb</td>
<td>75.0</td>
<td>72.2</td>
</tr>
<tr>
<td>PKN2</td>
<td>72.2</td>
<td>72.2</td>
</tr>
<tr>
<td>PKN1</td>
<td>72.2</td>
<td>72.2</td>
</tr>
<tr>
<td>ROCK1</td>
<td>72.2</td>
<td>72.2</td>
</tr>
<tr>
<td>ROCK2</td>
<td>72.2</td>
<td>72.2</td>
</tr>
<tr>
<td>PKACg</td>
<td>72.2</td>
<td>75.0</td>
</tr>
<tr>
<td>PKCa</td>
<td>72.2</td>
<td>75.0</td>
</tr>
<tr>
<td>PKCe</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>PKCg</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>NDR1</td>
<td>69.4</td>
<td>72.2</td>
</tr>
<tr>
<td>NDR2</td>
<td>69.4</td>
<td>72.2</td>
</tr>
<tr>
<td>MASTL</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>MRCKb</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>DMPK2</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>MRCKa</td>
<td>69.4</td>
<td>69.4</td>
</tr>
<tr>
<td>SGK</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKN3</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKCt</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKCd</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKCh</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKCb</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>PKCa</td>
<td>66.7</td>
<td>66.7</td>
</tr>
<tr>
<td>MSK1</td>
<td>63.9</td>
<td>63.9</td>
</tr>
<tr>
<td>MSK2</td>
<td>63.9</td>
<td>63.9</td>
</tr>
<tr>
<td>CRIK</td>
<td>63.9</td>
<td>63.9</td>
</tr>
<tr>
<td>DMPK1</td>
<td>63.9</td>
<td>63.9</td>
</tr>
<tr>
<td>PRKX</td>
<td>63.9</td>
<td>61.1</td>
</tr>
<tr>
<td>PRKY</td>
<td>63.9</td>
<td>61.1</td>
</tr>
<tr>
<td>RSK4</td>
<td>61.1</td>
<td>63.9</td>
</tr>
<tr>
<td>RSK3</td>
<td>61.1</td>
<td>63.9</td>
</tr>
<tr>
<td>RSK2</td>
<td>61.1</td>
<td>63.9</td>
</tr>
<tr>
<td>YANK2</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>YANK3</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>YANK1</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>PKCi</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>SGK2</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>SGK3</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>AKT1</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>AKT2</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>AKT3</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>RHOK</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>GPRK7</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>MAST3</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>MAST4</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>MAST2</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>MAST1</td>
<td>61.1</td>
<td>61.1</td>
</tr>
<tr>
<td>RSK1</td>
<td>58.3</td>
<td>61.1</td>
</tr>
<tr>
<td>PKCz</td>
<td>58.3</td>
<td>58.3</td>
</tr>
<tr>
<td>GPRK6</td>
<td>58.3</td>
<td>58.3</td>
</tr>
<tr>
<td>GPRK5</td>
<td>58.3</td>
<td>58.3</td>
</tr>
<tr>
<td>GPRK4</td>
<td>58.3</td>
<td>58.3</td>
</tr>
<tr>
<td>PDK1</td>
<td>55.6</td>
<td>58.3</td>
</tr>
<tr>
<td>BARK2</td>
<td>55.6</td>
<td>55.6</td>
</tr>
<tr>
<td>BARK1</td>
<td>55.6</td>
<td>55.6</td>
</tr>
<tr>
<td>PKG1</td>
<td>55.6</td>
<td>52.8</td>
</tr>
<tr>
<td>p70S6K</td>
<td>52.8</td>
<td>52.8</td>
</tr>
<tr>
<td>p70S6Kb</td>
<td>50.0</td>
<td>50.0</td>
</tr>
<tr>
<td>KgK494</td>
<td>44.4</td>
<td>44.4</td>
</tr>
<tr>
<td>RSKL2</td>
<td>27.8</td>
<td>27.8</td>
</tr>
</tbody>
</table>
Table S3. Target enzymes binding more potently than LATS1. Related to Figure 3. Of 314 kinases in a binding panel, these enzymes bound 1 µM TRULI more strongly than did Lats1 or Lats2. The assay did not test for functional inhibition.

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Affinity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLK4</td>
<td>102.191</td>
</tr>
<tr>
<td><strong>PRKCCQ</strong></td>
<td><strong>99.155</strong></td>
</tr>
<tr>
<td>CDC7</td>
<td>99.093</td>
</tr>
<tr>
<td>DMPK</td>
<td>97.919</td>
</tr>
<tr>
<td>CDC42BPA</td>
<td>97.161</td>
</tr>
<tr>
<td>HIPK3</td>
<td>95.798</td>
</tr>
<tr>
<td>HIPK2</td>
<td>94.205</td>
</tr>
<tr>
<td><strong>PRKACB</strong></td>
<td><strong>92.922</strong></td>
</tr>
<tr>
<td>CLK2</td>
<td>92.819</td>
</tr>
<tr>
<td>GSK3B</td>
<td>92.698</td>
</tr>
<tr>
<td><strong>PRKCH</strong></td>
<td><strong>90.416</strong></td>
</tr>
<tr>
<td>CDK19</td>
<td>90.205</td>
</tr>
<tr>
<td>PKN2</td>
<td>89.660</td>
</tr>
<tr>
<td>CDK8</td>
<td>88.778</td>
</tr>
<tr>
<td>PRKX</td>
<td>88.131</td>
</tr>
<tr>
<td>BMP2K</td>
<td>86.274</td>
</tr>
<tr>
<td>HIPK1</td>
<td>86.064</td>
</tr>
<tr>
<td>DYRK1A</td>
<td>85.826</td>
</tr>
<tr>
<td>PASK</td>
<td>85.771</td>
</tr>
<tr>
<td><strong>ROCK2</strong></td>
<td><strong>84.111</strong></td>
</tr>
<tr>
<td>CDC42BPG</td>
<td>83.657</td>
</tr>
<tr>
<td>PAK4</td>
<td>83.440</td>
</tr>
<tr>
<td>DYRK1B</td>
<td>81.514</td>
</tr>
<tr>
<td>TGFBR2</td>
<td>81.311</td>
</tr>
<tr>
<td>LRRK2</td>
<td>81.277</td>
</tr>
<tr>
<td><strong>ROCK1</strong></td>
<td><strong>79.232</strong></td>
</tr>
<tr>
<td>PRKG2</td>
<td>79.109</td>
</tr>
<tr>
<td>CLK1</td>
<td>78.062</td>
</tr>
<tr>
<td><strong>PRKCD</strong></td>
<td><strong>77.995</strong></td>
</tr>
<tr>
<td>PKN1</td>
<td>77.735</td>
</tr>
<tr>
<td>MAP4K4</td>
<td>77.535</td>
</tr>
<tr>
<td>DAPK3</td>
<td>77.096</td>
</tr>
<tr>
<td>TAOK1</td>
<td>76.404</td>
</tr>
<tr>
<td><strong>LATS2</strong></td>
<td><strong>74.882</strong></td>
</tr>
<tr>
<td>MAP3K7</td>
<td>74.047</td>
</tr>
<tr>
<td><strong>LATS1</strong></td>
<td><strong>73.903</strong></td>
</tr>
</tbody>
</table>
Table S4. Half-maximal inhibitory concentrations ($IC_{50}$s) of TRULI for selected kinases. Related to Figure 3.

<table>
<thead>
<tr>
<th>Kinase</th>
<th>$IC_{50}$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKA</td>
<td>60</td>
</tr>
<tr>
<td>PKCepsilon</td>
<td>14</td>
</tr>
<tr>
<td>ROCK1</td>
<td>88</td>
</tr>
<tr>
<td>NDR1</td>
<td>1000</td>
</tr>
</tbody>
</table>


9. Collado, M. S. *et al.* The Postnatal Accumulation of Junctional E-Cadherin Is Inversely Correlated with the Capacity for Supporting Cells to Convert Directly into


45. Hirozane, Y. et al. Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application. 


46.http://www.reactionbiology.com/webapps/site/kinaseassay.aspx?gclid=EAIaIQobChMI9K2248-V5wlVyp6zCh2HSwAKEAYASABEgJCsPD_BwE.


